US20050153941A1 - Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line - Google Patents
Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line Download PDFInfo
- Publication number
- US20050153941A1 US20050153941A1 US10/875,194 US87519404A US2005153941A1 US 20050153941 A1 US20050153941 A1 US 20050153941A1 US 87519404 A US87519404 A US 87519404A US 2005153941 A1 US2005153941 A1 US 2005153941A1
- Authority
- US
- United States
- Prior art keywords
- group
- stem cell
- hydrogen atom
- lower alkyl
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 346
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 175
- 239000003795 chemical substances by application Substances 0.000 title claims description 180
- 239000001963 growth medium Substances 0.000 title claims description 39
- 238000004113 cell culture Methods 0.000 title abstract description 31
- 210000004748 cultured cell Anatomy 0.000 title description 2
- 230000004069 differentiation Effects 0.000 claims abstract description 126
- 210000000130 stem cell Anatomy 0.000 claims abstract description 126
- 210000001671 embryonic stem cell Anatomy 0.000 claims abstract description 86
- 238000000034 method Methods 0.000 claims abstract description 80
- 238000012258 culturing Methods 0.000 claims abstract description 42
- 150000003384 small molecules Chemical class 0.000 claims abstract description 42
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims description 200
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 156
- 125000000217 alkyl group Chemical group 0.000 claims description 132
- -1 hydroxycarbonyl group Chemical group 0.000 claims description 74
- 230000024245 cell differentiation Effects 0.000 claims description 71
- 125000002252 acyl group Chemical group 0.000 claims description 65
- 125000003545 alkoxy group Chemical group 0.000 claims description 59
- 150000003839 salts Chemical class 0.000 claims description 58
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 50
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 50
- 230000014509 gene expression Effects 0.000 claims description 49
- 125000005843 halogen group Chemical group 0.000 claims description 47
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 41
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 31
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 31
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 29
- 101150012532 NANOG gene Proteins 0.000 claims description 24
- 125000002560 nitrile group Chemical group 0.000 claims description 21
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 19
- 102000004495 STAT3 Transcription Factor Human genes 0.000 claims description 19
- 230000009471 action Effects 0.000 claims description 18
- 238000002054 transplantation Methods 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 17
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 125000002947 alkylene group Chemical group 0.000 claims description 15
- 125000004429 atom Chemical group 0.000 claims description 15
- 229940002612 prodrug Drugs 0.000 claims description 13
- 239000000651 prodrug Substances 0.000 claims description 13
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 claims description 11
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 11
- QNBJDLSBBZVXNW-UHFFFAOYSA-N C1=CC(C(=O)C)=CC=C1N=NC(C(O)=O)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound C1=CC(C(=O)C)=CC=C1N=NC(C(O)=O)=C1C2=CC=CC=C2CC(C)(C)N1 QNBJDLSBBZVXNW-UHFFFAOYSA-N 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 125000005842 heteroatom Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 7
- 238000001727 in vivo Methods 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims description 5
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims description 5
- 125000005181 hydroxyalkylaminoalkyl group Chemical group 0.000 claims description 5
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 4
- LVDRQRPNKHMEME-UHFFFAOYSA-N 2-(2-acetyl-3,3-dimethyl-4h-isoquinolin-1-ylidene)-2-[(4-acetylphenyl)diazenyl]acetamide Chemical compound C12=CC=CC=C2CC(C)(C)N(C(=O)C)C1=C(C(N)=O)N=NC1=CC=C(C(C)=O)C=C1 LVDRQRPNKHMEME-UHFFFAOYSA-N 0.000 claims description 4
- VEQRBCZWJQYGOS-UHFFFAOYSA-N 2-[(4-acetylphenyl)diazenyl]-2-(2,3,3-trimethyl-4h-isoquinolin-1-ylidene)acetamide Chemical compound C12=CC=CC=C2CC(C)(C)N(C)C1=C(C(N)=O)N=NC1=CC=C(C(C)=O)C=C1 VEQRBCZWJQYGOS-UHFFFAOYSA-N 0.000 claims description 4
- WQFHCZGUBRVAAW-UHFFFAOYSA-N 2-[(4-acetylphenyl)diazenyl]-2-(3,3-dimethyl-2,4-dihydro-1h-isoquinolin-1-yl)acetamide Chemical compound C1=CC(C(=O)C)=CC=C1N=NC(C(N)=O)C1C2=CC=CC=C2CC(C)(C)N1 WQFHCZGUBRVAAW-UHFFFAOYSA-N 0.000 claims description 4
- UUHILQYSJGJSIA-UHFFFAOYSA-N C1=CC(C(=O)C)=CC=C1N=NC(C#N)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound C1=CC(C(=O)C)=CC=C1N=NC(C#N)=C1C2=CC=CC=C2CC(C)(C)N1 UUHILQYSJGJSIA-UHFFFAOYSA-N 0.000 claims description 4
- UTJDLLNFLCWVPU-UHFFFAOYSA-N C1=CC(C(=O)C)=CC=C1N=NC(C(=O)NC=1C=CC=CC=1)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound C1=CC(C(=O)C)=CC=C1N=NC(C(=O)NC=1C=CC=CC=1)=C1C2=CC=CC=C2CC(C)(C)N1 UTJDLLNFLCWVPU-UHFFFAOYSA-N 0.000 claims description 4
- HYZCNQMKWKNVCF-UHFFFAOYSA-N CC(=O)C1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 Chemical compound CC(=O)C1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 HYZCNQMKWKNVCF-UHFFFAOYSA-N 0.000 claims description 4
- JLCLSIGDGYWAKQ-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(=O)N(C)C)N=NC1=CC=C(C(C)=O)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(=O)N(C)C)N=NC1=CC=C(C(C)=O)C=C1 JLCLSIGDGYWAKQ-UHFFFAOYSA-N 0.000 claims description 4
- JAFORNOMBFOBFV-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(=O)NC)N=NC1=CC=C(C(C)=O)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(=O)NC)N=NC1=CC=C(C(C)=O)C=C1 JAFORNOMBFOBFV-UHFFFAOYSA-N 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
- 239000007788 liquid Substances 0.000 abstract description 19
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 abstract 4
- 239000000243 solution Substances 0.000 description 87
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 68
- 0 CCC.[1*]C1=CC=C([4*])C([3*])=C1[2*] Chemical compound CCC.[1*]C1=CC=C([4*])C([3*])=C1[2*] 0.000 description 42
- 235000002639 sodium chloride Nutrition 0.000 description 42
- 241000699666 Mus <mouse, genus> Species 0.000 description 40
- 239000000203 mixture Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 38
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 238000006243 chemical reaction Methods 0.000 description 35
- 239000002904 solvent Substances 0.000 description 30
- 210000001519 tissue Anatomy 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 26
- 239000002609 medium Substances 0.000 description 26
- 239000000463 material Substances 0.000 description 23
- 101150033839 4 gene Proteins 0.000 description 22
- 241000282567 Macaca fascicularis Species 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 22
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- 108010010803 Gelatin Proteins 0.000 description 21
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 21
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 21
- 238000003556 assay Methods 0.000 description 21
- 229920000159 gelatin Polymers 0.000 description 21
- 239000008273 gelatin Substances 0.000 description 21
- 235000019322 gelatine Nutrition 0.000 description 21
- 235000011852 gelatine desserts Nutrition 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 239000007795 chemical reaction product Substances 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 239000012981 Hank's balanced salt solution Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000012911 assay medium Substances 0.000 description 15
- 239000000126 substance Substances 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000006143 cell culture medium Substances 0.000 description 14
- 238000012136 culture method Methods 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 238000011002 quantification Methods 0.000 description 14
- 238000010186 staining Methods 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 13
- 229920000642 polymer Polymers 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 239000011148 porous material Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 210000003014 totipotent stem cell Anatomy 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 229940088598 enzyme Drugs 0.000 description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 241000288906 Primates Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000032050 esterification Effects 0.000 description 10
- 238000005886 esterification reaction Methods 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- 210000003754 fetus Anatomy 0.000 description 9
- 210000001161 mammalian embryo Anatomy 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 229910001868 water Inorganic materials 0.000 description 9
- ALJIEVIJBAJISI-UHFFFAOYSA-N 2-[(4-acetylphenyl)hydrazinylidene]-2-(3,3-dimethyl-4H-isoquinolin-1-yl)acetamide Chemical compound C1=CC(C(=O)C)=CC=C1NN=C(C(N)=O)C1=NC(C)(C)CC2=CC=CC=C12 ALJIEVIJBAJISI-UHFFFAOYSA-N 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 239000012954 diazonium Substances 0.000 description 8
- 150000001989 diazonium salts Chemical class 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 239000008107 starch Substances 0.000 description 8
- 235000019698 starch Nutrition 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 150000001408 amides Chemical class 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 235000010980 cellulose Nutrition 0.000 description 6
- 239000008367 deionised water Substances 0.000 description 6
- 229910021641 deionized water Inorganic materials 0.000 description 6
- 229940113088 dimethylacetamide Drugs 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 108010082117 matrigel Proteins 0.000 description 6
- 210000002894 multi-fate stem cell Anatomy 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 5
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 235000010288 sodium nitrite Nutrition 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 5
- 229940086542 triethylamine Drugs 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- LCYIZBVMHJGJGP-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone;hydrochloride Chemical compound Cl.CC(=O)C1=CC=C(N)C=C1 LCYIZBVMHJGJGP-UHFFFAOYSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical class OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 229960004106 citric acid Drugs 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 229940126864 fibroblast growth factor Drugs 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000012192 staining solution Substances 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- OCSAAQJVUMSJQZ-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(=O)OCC)N=NC1=CC=C(C(C)=O)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(=O)OCC)N=NC1=CC=C(C(C)=O)C=C1 OCSAAQJVUMSJQZ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- SAQUSDSPQYQNBG-UHFFFAOYSA-N chembl355496 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC(Br)=CC=C21 SAQUSDSPQYQNBG-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 3
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- UHVGDYSFPLSXDJ-UHFFFAOYSA-N n-(phenylhydrazinylidene)acetamide Chemical class CC(=O)N=NNC1=CC=CC=C1 UHVGDYSFPLSXDJ-UHFFFAOYSA-N 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 2
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- SARKXLKWFKNUMR-UHFFFAOYSA-N 4-benzamido-5-chloro-2-methylbenzenediazonium;chloride Chemical compound [Cl-].C1=C([N+]#N)C(C)=CC(NC(=O)C=2C=CC=CC=2)=C1Cl SARKXLKWFKNUMR-UHFFFAOYSA-N 0.000 description 2
- JIEINYQEXWLMCU-UHFFFAOYSA-N 7-bromo-3-hydroxy-n-(2-methoxyphenyl)naphthalene-2-carboxamide Chemical compound COC1=CC=CC=C1NC(=O)C1=CC2=CC(Br)=CC=C2C=C1O JIEINYQEXWLMCU-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- YMOUMBLAHTXJKV-UHFFFAOYSA-N C1=CC(OC)=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound C1=CC(OC)=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 YMOUMBLAHTXJKV-UHFFFAOYSA-N 0.000 description 2
- HKJVWUIGFHYUNC-UHFFFAOYSA-N CC1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 Chemical compound CC1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 HKJVWUIGFHYUNC-UHFFFAOYSA-N 0.000 description 2
- MGVDIAPPYLZUSV-UHFFFAOYSA-N COC1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 Chemical compound COC1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 MGVDIAPPYLZUSV-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 101150112014 Gapdh gene Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 244000043261 Hevea brasiliensis Species 0.000 description 2
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- WSTUZFYULZTRSV-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC(Cl)=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC(Cl)=C1 WSTUZFYULZTRSV-UHFFFAOYSA-N 0.000 description 2
- NAKGPWBQCDCQLN-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC([N+]([O-])=O)=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC([N+]([O-])=O)=C1 NAKGPWBQCDCQLN-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 241000242743 Renilla reniformis Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- QTENRWWVYAAPBI-YZTFXSNBSA-N Streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O QTENRWWVYAAPBI-YZTFXSNBSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 210000001654 germ layer Anatomy 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 229920003052 natural elastomer Polymers 0.000 description 2
- 229920001194 natural rubber Polymers 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000007447 staining method Methods 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 229940098466 sublingual tablet Drugs 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- NFHRNKANAAGQOH-UHFFFAOYSA-N triphenylstannane Chemical compound C1=CC=CC=C1[SnH](C=1C=CC=CC=1)C1=CC=CC=C1 NFHRNKANAAGQOH-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- YFVKIADDJIAGBP-UHFFFAOYSA-N 1-(2-methoxyphenyl)-2-methyl-3-nitroindol-6-ol Chemical compound COC1=CC=CC=C1N1C2=CC(O)=CC=C2C([N+]([O-])=O)=C1C YFVKIADDJIAGBP-UHFFFAOYSA-N 0.000 description 1
- GPRYKVSEZCQIHD-UHFFFAOYSA-N 1-(4-aminophenyl)ethanone Chemical compound CC(=O)C1=CC=C(N)C=C1 GPRYKVSEZCQIHD-UHFFFAOYSA-N 0.000 description 1
- VKQDQUKUVXGKRA-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-methyl-3-nitro-7-(piperidin-1-ylmethyl)indol-6-ol Chemical compound C1=CC(OC)=CC=C1N1C2=C(CN3CCCCC3)C(O)=CC=C2C([N+]([O-])=O)=C1C VKQDQUKUVXGKRA-UHFFFAOYSA-N 0.000 description 1
- JEBJJTQGDRPFNX-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-methyl-3-nitro-7-(piperidin-1-ylmethyl)indol-6-ol;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1N1C2=C(CN3CCCCC3)C(O)=CC=C2C([N+]([O-])=O)=C1C JEBJJTQGDRPFNX-UHFFFAOYSA-N 0.000 description 1
- VVZNWYXIOADGSW-UHFFFAOYSA-N 1-(4-methoxyphenyl)-2-methyl-3-nitroindol-6-ol Chemical compound C1=CC(OC)=CC=C1N1C2=CC(O)=CC=C2C([N+]([O-])=O)=C1C VVZNWYXIOADGSW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- JWIXHXMPUKXBSN-UHFFFAOYSA-N 2-[2-(4-methoxyanilino)ethenyl]-1-(4-methylphenyl)-3-nitroindol-6-ol Chemical compound C1=CC(OC)=CC=C1NC=CC1=C([N+]([O-])=O)C2=CC=C(O)C=C2N1C1=CC=C(C)C=C1 JWIXHXMPUKXBSN-UHFFFAOYSA-N 0.000 description 1
- MOIRJUBNJWFQEH-UHFFFAOYSA-N 2-[2-(dimethylamino)ethenyl]-1-(4-methoxyphenyl)-3-nitro-7-(piperidin-1-ylmethyl)indol-6-ol Chemical compound C1=CC(OC)=CC=C1N1C2=C(CN3CCCCC3)C(O)=CC=C2C([N+]([O-])=O)=C1C=CN(C)C MOIRJUBNJWFQEH-UHFFFAOYSA-N 0.000 description 1
- YPQMYQKFVYGMMW-UHFFFAOYSA-N 2-[2-(dimethylamino)ethenyl]-1-(4-methoxyphenyl)-7-(morpholin-4-ylmethyl)-3-nitroindol-6-ol Chemical compound C1=CC(OC)=CC=C1N1C2=C(CN3CCOCC3)C(O)=CC=C2C([N+]([O-])=O)=C1C=CN(C)C YPQMYQKFVYGMMW-UHFFFAOYSA-N 0.000 description 1
- RKAJCIAQWYAAJJ-UHFFFAOYSA-N 2-[2-(dimethylamino)ethenyl]-7-[(dimethylamino)methyl]-1-(4-methoxyphenyl)-3-nitroindol-6-ol Chemical compound C1=CC(OC)=CC=C1N1C2=C(CN(C)C)C(O)=CC=C2C([N+]([O-])=O)=C1C=CN(C)C RKAJCIAQWYAAJJ-UHFFFAOYSA-N 0.000 description 1
- IZJMWZVDDPBOIN-UHFFFAOYSA-N 2-[2-(dimethylamino)ethenyl]-7-[(dimethylamino)methyl]-1-(4-methylphenyl)-3-nitroindol-6-ol Chemical compound C1=2C(CN(C)C)=C(O)C=CC=2C([N+]([O-])=O)=C(C=CN(C)C)N1C1=CC=C(C)C=C1 IZJMWZVDDPBOIN-UHFFFAOYSA-N 0.000 description 1
- YGZFYDFBHIDIBH-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCC(CO)N(CCO)CCO YGZFYDFBHIDIBH-UHFFFAOYSA-N 0.000 description 1
- GOKJYAGJIKHEPU-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(2,4-dimethylphenyl)acetamide Chemical compound CC1=CC(C)=CC=C1NC(=O)C(C#N)=C1C2=CC=CC=C2CC(C)(C)N1 GOKJYAGJIKHEPU-UHFFFAOYSA-N 0.000 description 1
- GLMLPMCMLPZXIH-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(2-methylphenyl)acetamide Chemical compound CC1=CC=CC=C1NC(=O)C(C#N)=C1C2=CC=CC=C2CC(C)(C)N1 GLMLPMCMLPZXIH-UHFFFAOYSA-N 0.000 description 1
- KLYYCKRIJKCUDD-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(NC(=O)C(C#N)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 KLYYCKRIJKCUDD-UHFFFAOYSA-N 0.000 description 1
- FIVBUKNDIHKWOJ-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(NC(=O)C(C#N)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 FIVBUKNDIHKWOJ-UHFFFAOYSA-N 0.000 description 1
- YIHUOIJCIKHABC-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(3-nitrophenyl)acetamide Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C#N)C(=O)NC1=CC=CC([N+]([O-])=O)=C1 YIHUOIJCIKHABC-UHFFFAOYSA-N 0.000 description 1
- ZDOBASAMTAMXFX-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1NC(=O)C(C#N)=C1C2=CC=CC=C2CC(C)(C)N1 ZDOBASAMTAMXFX-UHFFFAOYSA-N 0.000 description 1
- HZPCPNXMDPUYCE-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(4-methylphenyl)acetamide Chemical compound C1=CC(C)=CC=C1NC(=O)C(C#N)=C1C2=CC=CC=C2CC(C)(C)N1 HZPCPNXMDPUYCE-UHFFFAOYSA-N 0.000 description 1
- VEJNHQMNROHIFT-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-(4-nitrophenyl)acetamide Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C#N)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 VEJNHQMNROHIFT-UHFFFAOYSA-N 0.000 description 1
- IHAMKSSHLSNUIB-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)-n-phenylacetamide Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C#N)C(=O)NC1=CC=CC=C1 IHAMKSSHLSNUIB-UHFFFAOYSA-N 0.000 description 1
- IBVYMJBNXJJGEY-UHFFFAOYSA-N 2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)acetamide Chemical compound C1=CC=C2C(=C(C#N)C(N)=O)NC(C)(C)CC2=C1 IBVYMJBNXJJGEY-UHFFFAOYSA-N 0.000 description 1
- DGJMPUGMZIKDRO-NJFSPNSNSA-N 2-cyanoacetamide Chemical class NC(=O)[14CH2]C#N DGJMPUGMZIKDRO-NJFSPNSNSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- GJTVVFZZFQCZBB-UHFFFAOYSA-N 2-methyl-1-(4-methylphenyl)-3-nitroindol-6-ol Chemical compound CC1=C([N+]([O-])=O)C2=CC=C(O)C=C2N1C1=CC=C(C)C=C1 GJTVVFZZFQCZBB-UHFFFAOYSA-N 0.000 description 1
- RIWRBSMFKVOJMN-UHFFFAOYSA-N 2-methyl-1-phenylpropan-2-ol Chemical compound CC(C)(O)CC1=CC=CC=C1 RIWRBSMFKVOJMN-UHFFFAOYSA-N 0.000 description 1
- XDPAIPMOMWBKEL-UHFFFAOYSA-N 2-methyl-3-nitro-1-phenylindol-6-ol Chemical compound CC1=C([N+]([O-])=O)C2=CC=C(O)C=C2N1C1=CC=CC=C1 XDPAIPMOMWBKEL-UHFFFAOYSA-N 0.000 description 1
- MUZDXNQOSGWMJJ-UHFFFAOYSA-N 2-methylprop-2-enoic acid;prop-2-enoic acid Chemical compound OC(=O)C=C.CC(=C)C(O)=O MUZDXNQOSGWMJJ-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- CKQHAYFOPRIUOM-UHFFFAOYSA-N 3'-Aminoacetophenone Chemical compound CC(=O)C1=CC=CC(N)=C1 CKQHAYFOPRIUOM-UHFFFAOYSA-N 0.000 description 1
- AEDQNOLIADXSBB-UHFFFAOYSA-N 3-(dodecylazaniumyl)propanoate Chemical compound CCCCCCCCCCCCNCCC(O)=O AEDQNOLIADXSBB-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- LDACRTGBIXQUOU-UHFFFAOYSA-N 7-(diethylaminomethyl)-1-(4-methoxyphenyl)-2-methyl-3-nitro-6-indolol Chemical compound C1=2C(CN(CC)CC)=C(O)C=CC=2C([N+]([O-])=O)=C(C)N1C1=CC=C(OC)C=C1 LDACRTGBIXQUOU-UHFFFAOYSA-N 0.000 description 1
- AUXXJCVRGURVMW-UHFFFAOYSA-N 7-[(3-hydroxypropylamino)methyl]-1-(4-methoxyphenyl)-2-methyl-3-nitroindol-6-ol;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1N1C2=C(CNCCCO)C(O)=CC=C2C([N+]([O-])=O)=C1C AUXXJCVRGURVMW-UHFFFAOYSA-N 0.000 description 1
- ONEHBQPFNTXVHM-UHFFFAOYSA-N 7-[(dimethylamino)methyl]-1-(4-methoxyphenyl)-2-methyl-3-nitroindol-6-ol Chemical compound C1=CC(OC)=CC=C1N1C2=C(CN(C)C)C(O)=CC=C2C([N+]([O-])=O)=C1C ONEHBQPFNTXVHM-UHFFFAOYSA-N 0.000 description 1
- WPTJAOOOLOMCIQ-UHFFFAOYSA-N 7-[(dimethylamino)methyl]-2-methyl-1-(4-methylphenyl)-3-nitroindol-6-ol Chemical compound C1=2C(CN(C)C)=C(O)C=CC=2C([N+]([O-])=O)=C(C)N1C1=CC=C(C)C=C1 WPTJAOOOLOMCIQ-UHFFFAOYSA-N 0.000 description 1
- FGZGOWHRLOCYLK-UHFFFAOYSA-N 7-[(dimethylamino)methyl]-2-methyl-3-nitro-1-phenylindol-6-ol Chemical compound C1=2C(CN(C)C)=C(O)C=CC=2C([N+]([O-])=O)=C(C)N1C1=CC=CC=C1 FGZGOWHRLOCYLK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 102100030374 Actin, cytoplasmic 2 Human genes 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 241001014327 Anodontia Species 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 206010004950 Birth mark Diseases 0.000 description 1
- UVHAHYGENDBKAP-UHFFFAOYSA-N C1=CC(C)=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound C1=CC(C)=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 UVHAHYGENDBKAP-UHFFFAOYSA-N 0.000 description 1
- DIJJPTDSFJDGBJ-UHFFFAOYSA-N C1=CC(NC(=O)C)=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound C1=CC(NC(=O)C)=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 DIJJPTDSFJDGBJ-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- UUHILQYSJGJSIA-WMBONIIHSA-N CC(=O)C1=CC=C(/N=N/C(C#N)=C2/NC(C)(C)CC3=CC=CC=C32)C=C1 Chemical compound CC(=O)C1=CC=C(/N=N/C(C#N)=C2/NC(C)(C)CC3=CC=CC=C32)C=C1 UUHILQYSJGJSIA-WMBONIIHSA-N 0.000 description 1
- JLCLSIGDGYWAKQ-MJJOXCQOSA-N CC(=O)C1=CC=C(/N=N/C(C(=O)N(C)C)=C2/NC(C)(C)CC3=CC=CC=C32)C=C1 Chemical compound CC(=O)C1=CC=C(/N=N/C(C(=O)N(C)C)=C2/NC(C)(C)CC3=CC=CC=C32)C=C1 JLCLSIGDGYWAKQ-MJJOXCQOSA-N 0.000 description 1
- UTJDLLNFLCWVPU-SCGOWUEXSA-N CC(=O)C1=CC=C(/N=N/C(C(=O)NC2=CC=CC=C2)=C2/NC(C)(C)CC3=CC=CC=C32)C=C1 Chemical compound CC(=O)C1=CC=C(/N=N/C(C(=O)NC2=CC=CC=C2)=C2/NC(C)(C)CC3=CC=CC=C32)C=C1 UTJDLLNFLCWVPU-SCGOWUEXSA-N 0.000 description 1
- QNBJDLSBBZVXNW-NVGBRHKGSA-N CC(=O)C1=CC=C(/N=N/C(C(=O)O)=C2/NC(C)(C)CC3=CC=CC=C32)C=C1 Chemical compound CC(=O)C1=CC=C(/N=N/C(C(=O)O)=C2/NC(C)(C)CC3=CC=CC=C32)C=C1 QNBJDLSBBZVXNW-NVGBRHKGSA-N 0.000 description 1
- ZXSRRUROLCGTBS-KEYVSXKFSA-N CC(=O)C1=CC=C(/N=N/C(C(N)=O)=C2/NC(C)(C)CC3=CC=CC=C32)C=C1 Chemical compound CC(=O)C1=CC=C(/N=N/C(C(N)=O)=C2/NC(C)(C)CC3=CC=CC=C32)C=C1 ZXSRRUROLCGTBS-KEYVSXKFSA-N 0.000 description 1
- LVDRQRPNKHMEME-MJJOXCQOSA-N CC(=O)C1=CC=C(/N=N/C(C(N)=O)=C2\C3=CC=CC=C3CC(C)(C)N2C(C)=O)C=C1 Chemical compound CC(=O)C1=CC=C(/N=N/C(C(N)=O)=C2\C3=CC=CC=C3CC(C)(C)N2C(C)=O)C=C1 LVDRQRPNKHMEME-MJJOXCQOSA-N 0.000 description 1
- VEQRBCZWJQYGOS-WMBONIIHSA-N CC(=O)C1=CC=C(/N=N/C(C(N)=O)=C2\C3=CC=CC=C3CC(C)(C)N2C)C=C1 Chemical compound CC(=O)C1=CC=C(/N=N/C(C(N)=O)=C2\C3=CC=CC=C3CC(C)(C)N2C)C=C1 VEQRBCZWJQYGOS-WMBONIIHSA-N 0.000 description 1
- WQFHCZGUBRVAAW-OCOZRVBESA-N CC(=O)C1=CC=C(/N=N/C(C(N)=O)C2NC(C)(C)CC3=CC=CC=C32)C=C1 Chemical compound CC(=O)C1=CC=C(/N=N/C(C(N)=O)C2NC(C)(C)CC3=CC=CC=C32)C=C1 WQFHCZGUBRVAAW-OCOZRVBESA-N 0.000 description 1
- HYZCNQMKWKNVCF-KEYVSXKFSA-N CC(=O)C1=CC=CC(/N=N/C(C(N)=O)=C2/NC(C)(C)CC3=CC=CC=C32)=C1 Chemical compound CC(=O)C1=CC=CC(/N=N/C(C(N)=O)=C2/NC(C)(C)CC3=CC=CC=C32)=C1 HYZCNQMKWKNVCF-KEYVSXKFSA-N 0.000 description 1
- QRVXDQNZYITBPH-UHFFFAOYSA-N CC(=O)C1=CC=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 Chemical compound CC(=O)C1=CC=CC=C1N=NC(C(N)=O)=C1C2=CC=CC=C2CC(C)(C)N1 QRVXDQNZYITBPH-UHFFFAOYSA-N 0.000 description 1
- XPBPXOCYYOHHLJ-UHFFFAOYSA-N CC(=O)NC1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 Chemical compound CC(=O)NC1=CC=CC(N=NC(C(N)=O)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 XPBPXOCYYOHHLJ-UHFFFAOYSA-N 0.000 description 1
- OCSAAQJVUMSJQZ-MJJOXCQOSA-N CCOC(=O)C(/N=N/C1=CC=C(C(C)=O)C=C1)=C1\NC(C)(C)CC2=CC=CC=C21 Chemical compound CCOC(=O)C(/N=N/C1=CC=C(C(C)=O)C=C1)=C1\NC(C)(C)CC2=CC=CC=C21 OCSAAQJVUMSJQZ-MJJOXCQOSA-N 0.000 description 1
- JAFORNOMBFOBFV-ACNFXJTLSA-N CNC(=O)C(/N=N/C1=CC=C(C(C)=O)C=C1)=C1\NC(C)(C)CC2=CC=CC=C21 Chemical compound CNC(=O)C(/N=N/C1=CC=C(C(C)=O)C=C1)=C1\NC(C)(C)CC2=CC=CC=C21 JAFORNOMBFOBFV-ACNFXJTLSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000942966 Mus musculus Leukemia inhibitory factor Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- BNBOUMIJPUPSKC-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(Br)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(Br)C=C1 BNBOUMIJPUPSKC-UHFFFAOYSA-N 0.000 description 1
- ICSKFBZOZMUFRY-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(Cl)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(Cl)C=C1 ICSKFBZOZMUFRY-UHFFFAOYSA-N 0.000 description 1
- MWJAJPFUSWPTEN-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(S(N)(=O)=O)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C(S(N)(=O)=O)C=C1 MWJAJPFUSWPTEN-UHFFFAOYSA-N 0.000 description 1
- IDQAJIUSPXWBBJ-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C([N+]([O-])=O)C=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=C([N+]([O-])=O)C=C1 IDQAJIUSPXWBBJ-UHFFFAOYSA-N 0.000 description 1
- IHVDURBVOODYKG-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC(Br)=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC(Br)=C1 IHVDURBVOODYKG-UHFFFAOYSA-N 0.000 description 1
- BSRJGMWXNNJOBZ-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC(S(N)(=O)=O)=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC(S(N)(=O)=O)=C1 BSRJGMWXNNJOBZ-UHFFFAOYSA-N 0.000 description 1
- TVHCFJIPMCSUJA-UHFFFAOYSA-N N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC=C1 Chemical compound N1C(C)(C)CC2=CC=CC=C2C1=C(C(N)=O)N=NC1=CC=CC=C1 TVHCFJIPMCSUJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 201000009859 Osteochondrosis Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- PHUMYNOPYMKMNR-UHFFFAOYSA-N [6-acetyloxy-2-methyl-1-(4-methylphenyl)-3-nitroindol-7-yl]methyl acetate Chemical compound C1=2C(COC(=O)C)=C(OC(C)=O)C=CC=2C([N+]([O-])=O)=C(C)N1C1=CC=C(C)C=C1 PHUMYNOPYMKMNR-UHFFFAOYSA-N 0.000 description 1
- PZZCIOGSQRXPIF-UHFFFAOYSA-N [H]C(C(N)=O)=C1NC(C)(C)CC2=CC=CC=C21 Chemical compound [H]C(C(N)=O)=C1NC(C)(C)CC2=CC=CC=C21 PZZCIOGSQRXPIF-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005075 adamantyloxy group Chemical group C12(CC3CC(CC(C1)C3)C2)O* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 230000005212 anodontia Effects 0.000 description 1
- 206010002583 anodontia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000007698 birth defect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- DGJMPUGMZIKDRO-UHFFFAOYSA-N cyanoacetamide Chemical compound NC(=O)CC#N DGJMPUGMZIKDRO-UHFFFAOYSA-N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000005117 dialkylcarbamoyl group Chemical group 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002514 epidermal stem cell Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- YEYFBORKGWMADM-UHFFFAOYSA-N ethyl 3-[[2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)acetyl]amino]benzoate Chemical compound CCOC(=O)C1=CC=CC(NC(=O)C(C#N)=C2C3=CC=CC=C3CC(C)(C)N2)=C1 YEYFBORKGWMADM-UHFFFAOYSA-N 0.000 description 1
- GZNBKIUMIZHMEY-UHFFFAOYSA-N ethyl 4-[[2-cyano-2-(3,3-dimethyl-2,4-dihydroisoquinolin-1-ylidene)acetyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)C(C#N)=C1C2=CC=CC=C2CC(C)(C)N1 GZNBKIUMIZHMEY-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001647 gastrula Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 210000003105 phrenic nerve Anatomy 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 150000003459 sulfonic acid esters Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Definitions
- the present invention relates to a stem cell differentiation inhibiting agent comprising a low molecular weight compound, especially a tetrahydroisoquinoline derivative, as an active ingredient, a stem cell culture method by using the same, a culture medium, and a cultured stem cell line prepared by using the same.
- the present invention relates further to new bicyclic compounds having an action of maintaining an undifferentiated state of the stem cell.
- An organ and a tissue damaged by an injury, a disease or aging require promotion of regeneration to recover its function.
- a substantial organ such as heart, liver, kidney, or pancreas is essential for maintaining life, and thus hypofunction and a function thereof causes a death. Therefore transplantation treatment such as organ transplantation is popularly conducted intending life saving.
- the number of donor is generally insufficient, and thus a new approach to solve the problem is necessary.
- stem cell which is present in an embryo or an adult and may have an ability of dividing indefinitely to differentiate in one or a plurality of directions, to prepare the tissue and the organ for repairing a defect tissue, attracts attention as a therapeutic method without the defect of the conventional organ transplantation.
- the stem cell is grown and then differentiated to be used for cell transplantation and, through use of an artificial support tissue and artificial tissue construction, the artificial tissue is transplanted into a living body and is used as an artificial organ. It is expected that using the stem cell for cell transplantation therapy and tissue engineering allows solving the problem, which includes a defect of a tissue after a transplanting piece is resected from the donor and the shortage of the donor, in transplantation therapy including conventional autotransplantation.
- the stem cell has been identified from many organs such as a blood vessel, nerve, blood, cartilage, bone, liver, pancreas. Particularly among them, a totipotent stem cell having the ability of differentiating in all cell types gets a lot of attention as a cell that can provide easily a cell and a tissue used for the aforementioned regeneration medicine field and also drug creation and gene therapy.
- Embryonic Stem hereafter ES
- EG Embryonic Germ
- the ES cell is a cell line isolated from an Inner Cell Mass (ICM) of a blastocyst stage of a mouse (Evans et al., Nature, 292: 154, 1981). Cells consisting an individual are derived from a primary ectoderm produced from an Inner Cell Mass (hereafter ICM) of the blastocyst stage or an epiblast of a gastrula, and the ICM and the epiblast are a stem cell group having the totipotency.
- ICM Inner Cell Mass
- the ES cell has the ability of the differentiation into various kinds of tissues to form the individual and forms a normal embryo and a chimeric embryo to differ into any mature cells of the adult.
- the ES cell has the ability of producing such various cells as blood cells, myocardial cell, vascular endothelial cell, nerve cell, pigment cell, pancreatic incretion cell depending on the condition of in vitro differentiation induction (Nakano, T. Saisin Igaku Bessatsu: Regeneration medicine: 81-89. 2000).
- the EG cell is a cell line established by culturing a primordial germ cell in presence of LIF (Leukemia Inhibitory Factor) and bFGF (basic Fibroblast Growth Factor) (Matsui et al., Cell 70: 84. 1992; Resnic et al., Nature 359: 550. 1992) and has ability of differentiation into various tissues as in the case of the ES cell.
- LIF Leukemia Inhibitory Factor
- bFGF basic Fibroblast Growth Factor
- LIF leukemia inhibitory factor
- PD98059 Cell Signaling Technology Corp. made
- the action of PD98059 depends on LIF and does not express independently the effect (Burdon et al., Dev. Biol. 210: p 30, 1999) and, hence, the aforementioned problem is not solved.
- the differentiation inhibiting agent according to the present invention comprises a low molecular weight compound as the active ingredient. It has been not so far known that a low molecular weight compound maintains the undifferentiated status of the totipotent stem cell. Therefore, the action of maintaining undifferentiation of the totipotent stem cell which is possessed by the low molecular weight compound represented by the formulae (1) to (10) shown in this specification, has not been known at all so far.
- the object of the present invention is to provide a differentiation inhibiting agent which allows culture of a stem cell or an embryonic stem cell in an undifferentiated state without use of any feeder cell or any component derived from the feeder cell.
- the object of the present invention is to provide a method for culturing the stem cell or the embryonic stem cell in an undifferentiated state by using such the differentiation inhibiting agent without use of any feeder cell or any component derived from the feeder cell, and to provide a cell culture liquid which comprises such the differentiation inhibiting agent, and to provide a cell line prepared by culturing using such the differentiation inhibiting agent.
- Another object of the present invention is to provide a novel bicyclic compound enabling culture of the stem cell or the embryonic stem cell in the undifferentiated state without use of any feeder cell or any component derived from the feeder cell.
- the present invention was achieved to solve the above objects and relates to a differentiation inhibiting agent allowing culture of a stem cell or an embryonic stem cell in an undifferentiated state, a method for culturing the stem cell or the embryonic stem cell by using such the differentiation inhibiting agent, a cell culture liquid comprising such the differentiation inhibiting agent, and a cell line prepared by culturing using such the differentiation inhibiting agent.
- the present invention includes the followings:
- a stem cell differentiation inhibiting agent which comprises a low molecular weight compound or a salt thereof as an active ingredient.
- the low molecular weight compound is a compound represented by the formula (1): wherein, R 1 , R 2 , R 3 and R 4 may be the same or different, each representing an electron-withdrawing group, an electron-donating group or a hydrogen atom; ring A represents 5- to 8-member ring containing at least 1 hetero atom in the ring; X represents an alkylene group of which atomic number of a main chain ranges from 0 to 10; the alkylene group having the atomic number of 0 represents a single bond; one or more ethylene groups constituting the alkylene group may be replaced by —C ⁇ C— group, and/or —N ⁇ N— group, and/or —CONH— group, and further the group may have a double bond bonding to the ring A; the alkylene group has 1 or more electron-withdrawing groups, electron-donating groups or hydrogen atoms as a substituent; G represents an aromatic group which may have an electron-withdrawing
- ring A is a 5- or 6-member ring containing at least 1 hetero atom selected from a group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, in the ring.
- the alkylene group represented by X includes 1 or more groups and/or atoms selected from the group consisting of an alkyl group, an acyl group, an alkoxy group, a nitro group, a hydroxycarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, a nitrile group and a halogen atom as a substituent.
- the low molecular weight compound is a compound represented by the formula (4): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are the same as those defined in (6) above; R 10 , R 11 , R 12 and R 13 may be the same or different, each representing an electron-withdrawing group, an electron-donating group or a hydrogen atom; the double one-side broken line represents a single bond or a double bond; when the double one-side broken line represents a double bond, a wavy portion represents the presence of a geometric isomer; arrangement of these geometric isomers is not specially restricted, but may be any of an E isomer or a Z isomer each independently.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each independently groups or atoms selected from the group consisting of an alkyl group, an acyl group, an alkoxy group, a nitro group, a hydroxycarbonyl group, a nitrile group, an alkoxycarbonyl group, an aminocarbonyl group, a halogen atom and a hydrogen atom.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 and R 12 are each independently groups or atoms selected from the group consisting of an alkyl group, an acyl group, an alkoxy group, a nitro group, a hydroxycarbonyl group, a nitrile group, an alkoxycarbonyl group, an aminocarbonyl group, a halogen atom and a hydrogen atom.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each independently groups or atoms selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyl group, a nitro group, a nitrile group, an acetoxy group, an acetoxy alkyl group, a cyclic alkylaminoalkyl group which may contain an oxygen atom, a dialkylaminoalkyl group, a dialkylaminovinyl group, a hydroxyalkylaminoalkyl group, an arylaminovinyl group and a hydrogen atom.
- R 1 , R 2 , R 3 , R 4 , R 8 , R 9 and R 10 are hydrogen atoms;
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group;
- R 6 and R 7 are lower alkyl groups which may be the same or different;
- R 11 is a hydrogen atom, a halogen atom, a nitro group or a lower alkoxy group;
- R 12 is a hydrogen atom, a lower alkyl group, a lower acyl group or a lower alkoxy group;
- R 13 is a hydroxycarbonyl group, a nitrile group, an aminocarbonyl group or a lower alkoxycarbonyl group.
- R 1 , R 2 , R 3 , R 4 , R 8 and R 9 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 are lower alkyl groups which may be the same or different
- R 10 is a hydrogen atom or a lower alkyl group
- R 11 is a hydrogen atom, a halogen atom, a nitro group, a lower alkoxy group or a lower alkoxycarbonyl group
- R 12 is a hydrogen atom, a lower alkyl group, a lower acyl group or a lower alkoxy group.
- R 1 and R 2 are hydrogen atoms
- R 3 is a hydroxyl group or an acetoxy group
- R 4 is an acetoxy alkyl group, a cyclic alkylaminoalkyl group which may contain an oxygen atom, a dialkylaminoalkyl group, a hydroxyalkylaminoalkyl group or a hydrogen atom
- R 5 is a lower alkyl group or an arylaminovinyl group
- R 1 is a nitro group
- R 7 , R 8 and R 9 may be the same or different, each representing a lower alkyl group, a lower alkoxy group or a hydrogen atom.
- R 1 , R 2 , R 3 and R 4 may be the same or different, each representing a hydrogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group or a halogen atom;
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group;
- R 6 and R 7 may be the same or different, each representing a hydrogen atom, a lower alkyl group or a lower alkyl group which may form a ring structure;
- R 8 and R 9 are hydrogen atoms;
- R 10 , R 11 and R 12 may be the same or different, each representing a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group;
- R 13 represents a hydroxycarbonyl group; a lower alkoxycarbonyl group, a secondary aminocarbonyl group or a ter
- R 1 , R 2 , R 3 and R 4 may be the same or different, each representing a hydrogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group or a halogen atom;
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group;
- R 6 and R 7 may be the same or different, each representing a hydrogen atom, a lower alkyl group or a lower alkyl group which may form a ring structure;
- R 8 and R 9 are hydrogen atoms;
- R 10 and R 12 are a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group;
- R 11 is a lower acyl group;
- R 1 , R 2 , R 3 and R 4 may be the same or different, each representing a hydrogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group or a halogen group;
- R 5 is a lower acyl group or a lower alkyl group;
- R 1 and R 7 may be the same or different, each representing a hydrogen atom, a lower alkyl group or a lower alkyl group which may form a ring structure;
- R 8 and R 9 are hydrogen atoms;
- R 10 , R 11 and R 12 may be the same or different, each representing a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group;
- R 13 represents a hydroxycarbonyl group, a lower alkoxycarbonyl group or an aminocarbonyl group; the wavy lined portion represents the presence of the geometric is
- R 1 , R 2 , R 3 and R 4 may be the same or different, each representing a hydrogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group or a halogen atom;
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group;
- R 6 and R 7 may be the same or different, each representing a lower alkyl group or a lower alkyl group which may form a ring structure;
- R 8 and R 9 are hydrogen atoms;
- R 10 , R 11 and R 12 may be the same or different, each representing a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group;
- R 13 represents a nitrile group; the wavy lined portion represents the presence of the geometric isomer; arrangement of these geometric isomers is not specially restricted, but may be
- R 1 , R 2 , R 3 and R 4 may be the same or different, each representing a hydrogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group or a halogen atom;
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group;
- R 6 and R 7 may be the same or different, each representing a hydrogen atom, a lower alkyl group or a lower alkyl group which may form a ring structure;
- R 9 and R 9 are hydrogen atoms;
- R 10 , R 11 and R 12 may be the same or different, each representing a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group;
- R 13 represents a hydroxycarbonyl group, a lower alkoxycarbonyl group, an aminocarbonyl group or a nit
- R 1 , R 2 , R 3 and R 4 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 are lower alkyl groups which may be same or different from each other
- R 8 , R 9 and R 10 are hydrogen atoms
- R 11 and R 12 may be the same or different, each representing a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group
- R 13 is a hydroxycarbonyl group, a lower alkoxycarbonyl group, a mono-lower alkylaminocarbonyl group, a di-lower alkylaminocarbonyl group or a phenyl aminocarbonyl group.
- R 1 , R 2 , R 3 and R 4 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 are lower alkyl groups which may be the same or different
- R 8 , R 9 and R 10 are hydrogen atoms
- R 11 is a lower acyl group
- R 12 is a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group
- R 13 is a hydroxycarbonyl group, a lower alkoxycarbonyl group, a carbamoyl group, a mono-lower alkylaminocarbonyl group, a di-lower alkylaminocarbonyl group or a phenyl aminocarbonyl group, or a salt thereof.
- R 1 , R 2 , R 3 and R 4 are hydrogen atoms;
- R 5 is a lower acyl group or a lower alkyl group;
- R 6 and R 7 are lower alkyl groups which may be the same or different;
- R 8 , R 9 and R 10 are hydrogen atoms;
- R 11 and R 12 may be the same or different, each representing a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group;
- R 13 is a hydroxycarbonyl group, a lower alkoxycarbonyl group, a carbamoyl group, a mono-lower alkylaminocarbonyl group, a di-lower alkylaminocarbonyl group or a phenyl aminocarbonyl group.
- R 1 , R 2 , R 3 and R 4 are hydrogen atoms;
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group;
- R 6 and R 7 are lower alkyl groups which may be the same or different;
- R 8 , R 9 and R 10 are hydrogen atoms;
- R 11 and R 12 may be the same or different, each representing a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group;
- R 13 is a nitrile group.
- R 1 , R 2 , R 3 and R 4 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 are lower alkyl groups which may be the same or different
- R 8 , R 9 and R 10 are hydrogen atoms
- R 11 and R 12 may be the same or different, each representing a hydrogen atom, a halogen atom, a nitro group, a lower alkyl group, a lower acyl group or a lower alkoxy group
- R 13 is a hydroxycarbonyl group, a lower alkoxycarbonyl group, a carbamoyl group, a mono-lower alkylaminocarbonyl group, a di-lower alkylaminocarbonyl group, a phenyl aminocarbonyl group or a nitrile group.
- (31) The compound according to (21) above or a salt thereof, which is 2-(4-acetyl-phenylazo)-2-(3,3-dimethyl-1,2,3,4-tetrahydro-isoquinoline-1-yl)-acetamide.
- a stem cell differentiation inhibiting agent which comprises the compound according to any of (17) to (31) above or a salt thereof as an active ingredient.
- a pharmaceutical composition comprising the compound according to any of (17) to (31) above or a salt thereof or a prodrug thereof.
- FIG. 1 shows structure of the compound A according to the present invention.
- the compound A is a compound in which R 1 to R 12 of the formula (5) in FIG. 1 are represented by groups or elements presented in the table below.
- FIG. 2 shows structures of compounds B to F according to the present invention.
- the compounds B to F are compounds in which R 1 to R 13 of the formula (4) in FIG. 2 are represented by groups or elements presented in the table below.
- FIG. 3 shows a result of alkaline phosphatase quantification 1.
- FIG. 4 shows a result of alkaline phosphatase staining 1.
- FIG. 5 shows a result of STAT3 activation assay 1.
- FIG. 6 shows an Oct-3/4 gene expression level.
- FIG. 7 shows a nanog gene expression level.
- FIG. 8 shows a result of an average fluorescent strength in expression level evaluation 1 of SSEA-1 antigen.
- FIG. 9 shows structures of compounds a to o according to the present invention.
- R 1 to R 9 of formula (6) in FIG. 9 are represented by groups or elements presented in the table below.
- FIG. 10 shows a result of alkaline phosphatase quantification 2 when the differentiation inhibiting agent according to the present invention is used.
- FIG. 11 shows a result of an average fluorescent strength in expression level evaluation 2 of SSEA-1 antigen.
- FIG. 12 shows a result of STAT3 activation assay 2.
- FIG. 13 shows result 1 of ES cell subculture.
- FIG. 14 shows result 2 of ES cell subculture.
- FIG. 15 shows an embryonic stem cell undifferentiation-maitaining effect of the differentiation inhibiting agent according to the present invention.
- FIG. 16 shows an embryonic stem cell undifferentiation-maitaining effect (staining image) of the differentiation inhibiting agent according to the present invention.
- FIG. 17 shows structure of compound ⁇ circle over (1) ⁇ according to the present invention.
- R 1 to R 13 of formula (10) in FIG. 17 are represented by groups or elements presented in the table below.
- FIG. 18 shows structure of compound ⁇ circle over (2) ⁇ to ⁇ circle over (10) ⁇ according to the present invention.
- R 1 to R 13 of formula (9) in FIG. 18 are represented by groups or elements presented in the table below.
- FIG. 19 shows a staining image of alkaline phosphatase staining.
- Stem cell is a cell differentiable into other cell types, which are differentiable into other cell types having a specified function, in other words, finally differentiated cells or cell types in a narrower range.
- Totipotent stem cell is a cell differentiable into arbitrary cell types including multipotent cells or completely differentiated cells (in other words, cells that can no longer differentiate into various cells).
- Multipotent stem cell is a cell differentiable into not always all types but one of many different cell types.
- An example of the multipotent stem cells is a hematopoietic stem cell and this cell can differentiate into various blood cell types such as a lymphocyte and an erythrocyte.
- embryonic stem cell is a totipotent cell obtained from a morula or a blastocyst stage of an embryo particularly in a preimplantation phase among the stem cells, and also called ES cell.
- the embryonic stem cell is occasionally applied to the multipotent stem cell, which is determined as become a sperm or an ovum, originated from a primordial germ cell of the embryo or the fetus (young).
- this cell is occasionally called an Embryonic Germ (EG) cell, and may be distinguished from the embryonic stem cell.
- Embryonic stem cells used in this specification may be of any animal species and, for example, include the embryonic stem cells of primates including a human, and mammals other than primates such as mammals and avian.
- Totipotency is a state differentiable into arbitrary cell types including the multipotent cell or the completely differentiated cell (in other words, cells that can no longer differentiate into various cells).
- Multipotency is a state differentiable into not always all types but one of many different cell types.
- Undifferentiation is a state in which an arbitrary cell mass comprising 1 cell or a plurality of cells is a cell in a state of having an ability of differentiating into 1 or a plurality of cells in a further differentiated state, or a cell mass containing the cell.
- Feeder used in an aim of describing the present invention is that providing an environment in which the totipotent stem cell is plated thereon to help propagation of the plated totipotent stem cell.
- Feeder cell used in an aim of describing the present invention is a nontotipotent stem cell, on which the totipotent stem cell is plated, and the nontotipotent stem cell provides an environment to help propagation of the plated totipotent stem cell.
- Component derived from a cell all components derived from a cell, such as components secreted from the cell, contents and cell membrane components.
- the present invention provides a differentiation inhibiting agent allowing propagation and maintenance of the stem cell, preferably an embryonic stem cell, in a undifferentiated state, a culture method by using the differentiation inhibiting agent, a cell culture liquid prepared by using the differentiation inhibiting agent, and a cell line prepared by culturing the differentiation inhibiting agent.
- the differentiation inhibiting agent, the culture method, and the culture liquid provided according to the present invention propagate and maintain the undifferentiated embryonic stem cell more conveniently and safely than conventional.
- the culture method by using the differentiation inhibiting agent according to the present invention may also be used for screening regarding a specific differentiation-inducing factor and a useful combination of differentiation-inducing factors.
- the ability of propagating the undifferentiated embryonic stem cell by using the differentiation inhibiting agent and the culture method according to the present invention provides an important benefit including the ability of producing an embryonic stem cell line which has a single or a plurality of genetic modifications applicable importantly to a medical treatment.
- the differentiation inhibiting agent according to the present invention is a chemically stable low molecular weight compound. Any compound having an activity of maintaining the undifferentiated state of the stem cell can be used. However, preferably, the low molecular weight compound is exemplified by a compound represented by the following formula (1): wherein R 1 , R 2 , R 3 and R 1 may be the same or different, each representing an electron-withdrawing group, an electron-donating group or a hydrogen atom.
- the electron-donating group is a substituent which can donate an electron to a benzene ring, and the electron-withdrawing group is a substituent having a property of withdrawing a ⁇ electron on a benzene ring.
- the electron-donating group and the electron-withdrawing group can be defined as s ⁇ 0 and s>0, respectively (Kiso Yuuki Hannou Ron (Fundamental Theory of Organic Chemistry), Hasimoto et al., Sankyou Syuppan, 1997).
- the ring A represents a 5- to 8-member ring containing at least 1 hetero atom in the ring.
- X represents an alkylene group having the atom number of a main chain ranging from 0 to 10.
- the alkylene group having the atom number 0 means a single bond.
- 1 or more ethylene constituting the alkylene group may be substituted by —C ⁇ C— group and/or —N ⁇ N— group and/or —CONH— group. Further, the group may have a double bond bonding to the ring A.
- the alkylene group may have 1 or more electron-withdrawing groups, electron-donating groups or hydrogen atoms as a substituent.
- G represents an aromatic group which may have an electron-withdrawing group, an electron-donating group or a hydrogen atom.
- the ring A may have 1 or more electron-withdrawing groups and/or electron-donating groups as a substituent other than an —XG group.
- the ring A is a 5- or 6-member ring containing at least 1 hetero atom, which is selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, in the ring.
- the ring A is a 5- or 6-member ring containing 1 nitrogen atom in the ring.
- the 5-member ring is preferably an unsaturated ring and the 6-member ring is preferably a saturated ring.
- the alkylene group represented by X has 1 or more groups and/or atoms selected from the group consisting of an alkyl group, an acyl group, an alkoxy group, a nitro group, a hydroxycarbonyl group, an alkoxycarbonyl group, an aminocarbonyl group, a nitrile group and a halogen atom as a substituent.
- the example of the formula (1) includes a tetrahydroisoquinoline derivative represented by the formula (2) and an indole derivative represented by the formula (3).
- R 1 , R 2 , R 3 , R 4 , X and G are the same defined above
- R 5 , R 6 , R 7 , R 8 and R 9 may be the same or different, each representing an electron-withdrawing group, an electron-donating group or a hydrogen atom.
- R 1 , R 2 , R 3 , R 4 , X and G are the same as defined above
- R 5 and R 6 may be the same or different, each representing an electron-withdrawing group, an electron-donating group or a hydrogen atom.
- tetrahydroisoquinoline derivative represented by the formula (2) include a compound having the structures shown by the formula (4) or the formula (5) and a salt thereof.
- R 1 to R 13 may be the same or different, each representing an electron-withdrawing group, an electron-donating group or a hydrogen atom.
- R 1 to R 13 include the group or atom selected from the group consisting of an alkyl group, an acyl group, an alkoxy group, a nitro group, a hydroxycarbonyl group, a nitrile group, an alkoxycarbonyl group, an aminocarbonyl group, a halogen atom and a hydrogen atom.
- R 1 to R 4 , R 8 , R 9 , and R 10 are hydrogen atoms
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 are lower alkyl groups which may be the same or different
- R 11 is a hydrogen atom, a halogen atom, a nitro group or a lower alkoxy group
- R 12 is a hydrogen atom, a lower alkyl group, a lower acyl group or a lower alkoxy group
- R 13 is a hydroxycarbonyl group, a nitrile group, an aminocarbonyl group or a lower alkoxycarbonyl group.
- the lower alkyl group represented by R includes, for instance, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, 1-methylpropyl, n-hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 3,3-dimethylpropyl, 2-ethylbutyl and the like.
- Preferred is methyl.
- the lower alkoxy group represented by R includes, for example, mehtoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentoxy, hexyloxy, heptyloxy, octyloxy and the like. Preferred is methoxy.
- the halogen atom represented by R includes fluorine, chlorine, bromine, and iodine. Preferred is chlorine or bromine.
- the lower acyl group represented by R includes formyl, acetyl, propionyl, butyryl and the like. Preferred is acetyl.
- the lower alkyl group which may form a ring structure, represented by R includes cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. Preferred is cyclopentyl, cyclohexyl or cycloheptyl.
- the lower alkoxycarbonyl group represented by R includes methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl and the like. Preferred is methoxycarbonyl or ethoxycarbonyl.
- the aminocarbonyl represented by R includes, for example, —CONR 2 (each of Rs, which may be the same or different, represents a hydrogen atom, an above-exemplified lower alkyl group, or a phenyl group which may have a substituent) and the like.
- the secondary aminocarbonyl group represented by R includes, for example, —CONHR (R represents the above-exemplified lower alkyl group, or the phenyl group which may have a substituent) and the like.
- the tertiary aminocarbonyl group includes, for example, —CONR 2 (each of R 5 , which may be the same or different, represents the above-exemplified lower alkyl group, or a phenyl group which may have a substituent) and the like.
- An aminoalkyl group represented by R includes, for example, —(CH 2 ) n —NR 2 (n represents 1 to 8, preferably 1).
- Each of Rs which may be the same or different, includes a hydrogen atom, a lower alkyl group, a lower alkyl groups which may form a cyclic structure (the cyclic structure may contain 1 to 3 hetero atoms such as a nitrogen and an oxygen) and a phenyl group which may have a substituent.
- An acetoxyalkyl represented by R includes —(CH 2 ) n —OAc (n represents 1 to 8), preferably n is 1.
- the one-side broken double line in the formula (4) represents a single bond or a double bond.
- the wavy lined portions (2 sites) represent the presence of the geometric isomer.
- Arrangement of these geometric isomers is not specially restricted, but may be any of the E isomer or the Z isomer each independently.
- the compound according to the present invention may be an arbitrary mixture of geometric isomers having pure shapes based on these geometric isomeric patterns.
- R 1 to R 4 , R 8 and R 9 are hydrogen atoms
- R 10 is a hydrogen atom or a lower alkyl group
- R 5 is a hydrogen atom, a lower acyl group or a lower alkyl group
- R 6 and R 7 are lower alkyl groups, which may be the same or different
- R 11 is a hydrogen atom, a halogen atom, a nitro group, a lower alkoxy group or a lower alkoxycarbonyl group
- R 12 is a hydrogen atom, a lower alkyl group, a lower acyl group or a lower alkoxy group.
- formula (4) includes a compound in the formula (4) wherein the one-side broken double line is a double bond and R 13 is an aminocarbonyl group, and which is represented by the formula (7).
- More specific compounds which are the tetrahydroisoquinoline derivatives and represented by the before-described formula (4), include the following compounds:
- R 1 to R 4 and R 6 to R 12 include groups or atoms selected from the same or different electron-withdrawing groups, or electron-donating groups or hydrogen atoms.
- R 1 to R 4 and R 6 to R 12 include the group selected from the group consisting of an alkyl group, an alkenyl, an alkynyl, a phenyl group, a naphthyl group, a furyl group, a thienyl group, an alkoxy group, an alkylamino group, an alkylcarbonyl group, a benzoyl group, a naphthoyl group, a furoyl group, a tenoyl group, a dialkylcarbamoyl group, an acetyl group, a butanoyl group, a methoxycarbonyl group, a cycloalkyl group, a benzyloxy group, an
- R 1 to R 4 and R 6 to R 12 are preferably groups or atoms selected from the group consisting of an alkyl group, an acetyl group, an alkoxy group, a nitro group, a halogen atom and a hydrogen atom.
- Salts of the compounds represented by the formula (2) or (3) are preferably a pharmaceutically acceptable salt.
- a hydrochloride salt, a sulfate salt, a phosphate salt, a hydrobromate salt, a acetate salt, a maleate salt, a fumarate salt, a succinate salt, a methane sulfonate salt, a p-toluene sulfonate salt, a citrate salt and a tartarate salt may be formed.
- ester compounds of the compounds represented by the formula (4) or (5) are within the scope of the present invention and, for example, include a carboxylic acid ester, a sulfonic acid ester and an inorganic acid ester.
- the indole derivatives represented by the formula (3) include the compounds represented by the following formula (6): wherein R 1 to R 9 are same or different electron-withdrawing groups, electron-donating groups or hydrogen atoms. Among these, preferably, R 1 to R 9 include the group or atom selected from the group consisting of an alkyl group, an alkoxy group, a hydroxyl group, a nitro group, an acetoxy group, an aminoalkyl group, an acetoxyalkyl group, an aminovinyl group and a hydrogen atom.
- R 1 and R 2 are hydrogen atoms
- R 3 is an acetoxy group or a hydroxyl group
- R 4 is a hydrogen atom, a dialkylaminoalkyl group, a cyclic alkylaminoalkyl group, a hydroxyalkylaminoalkyl group or an acetoxy alkyl group
- R 5 is a lower alkyl group or an arylaminovinyl group
- R 6 is a nitro group
- R 7 to R 9 may be the same or different, each representing a lower alkyl group, a lower alkoxy group or a hydrogen atom.
- the compound according to the present invention can be prepared by conducting the methods described below and methods similar to them, or a publicly known method.
- the method for preparing the compound represented by the formula (9) is presented below:
- Preparation can be carried out by dissolving equal amounts of a thioether derivative (I) and a phenylazo acetamide derivative (II) in a proper solvent (for example, amide such as dimethyl formamide or dimethyl acetamide, ether such as tetrahydrofuran, or aromatic hydrocarbon such as benzene or toluene) not influencing badly on a reaction and refluxing up to the material is exhausted.
- a proper solvent for example, amide such as dimethyl formamide or dimethyl acetamide, ether such as tetrahydrofuran, or aromatic hydrocarbon such as benzene or toluene
- the derivative (I) can be prepared by a publicly known method (for example, refer to Khim. Geterotsikl. Soedin., No. 7, p 995 (1990) or purchased as a marketed product.
- the phenylazo acetamide derivative (II) can be prepared by a publicly known technique (Materialy Ural'sk. Soveshch. po Spektroskopii, 4th, Sverdlovsk 1963, p 205(1965), Bulletin de l'Academie Polonaise des Sciences, Serie des Sciences Chimiques, 14(1), p 29 (1966), Am. Chem. Soc., Div. Org. Coatings, Plastics Chem. Preprints, 23(2), p 486 (1963), Zhurnal Obshchei Khimii, 35(3), p 559 (1965), Zhurnal Obshchei Khimii, 32, p 526 (1962), etc.).
- the compound represented by the formula (9) can be also synthesized by the following scheme:
- the compound can be obtained by reacting the compound (IV), which is obtained by reacting a benzyl carbinol derivative with a 2-cyanoacetamide derivative in the presence of sulfuric acid, with a diazonium salt (V) in an aqueous alcohol solution, which does not influence badly on the reaction, in the presence of hydrochloric acid.
- a diazonium salt V
- various derivatives can be purchased as the marketed product, and further can be prepared by a publicly known method (for example, J. Gen. Chem. USSR, No. 6, p 1263 (1936)).
- the diazonium salt can be derived from a commercialized aminobenzene derivative by a publicly known method using hydrochloric acid and an aqueous solution of sodium nitrite.
- the compound wherein R 5 is a methyl group is prepared as follows. Preparation can be conducted by adding the compound (R 5 ⁇ —H) which is represented by the formula (4) and sodium carbonate to a proper solvent (for example, nitrile such as acetonitrile, ether such as tetrahydrofuran, or aromatic hydrocarbon such as benzene or toluene), which does not influence badly on the reaction, to dissolve them; dropping slowly a mixture obtained by dissolving methyl iodide in a proper solvent (for example, amide such as dimethylformamide or dimethylacetamide, ether such as tetrahydrofuran, or aromatic hydrocarbon such as benzene or toluene), and refluxing the obtained mixture.
- a proper solvent for example, nitrile such as acetonitrile, ether such as tetrahydrofuran, or aromatic hydrocarbon such as benzene or toluene
- a proper solvent for example, amide such as
- the compound wherein R 5 is an acetyl group is prepared as follows. Preparation can be conducted by dissolving the compound (R 5 ⁇ —H) represented by the formula (9) and dimethylaminopyridine in pyridine in an ice bath and adding acetic anhydride followed by stirring.
- the compound represented by the formula (11) is prepared as follows:
- Preparation can be conducted by dissolving the compound represented by the formula (9) in a proper solvent (for example, amide such as dimethylformamide or dimethylacetamide), which does not influence badly on the reaction, and dropping a solution obtained by dissolving thionyl chloride in a proper solvent (for example, amide such as dimethylformamide or dimethylacetamide), which does not influence badly on the reaction, in an ice bath.
- a proper solvent for example, amide such as dimethylformamide or dimethylacetamide
- Preparation can be conducted by adding potassium hydroxide and the compound represented by the formula (9) to ethanol followed by reflux.
- Preparation can be conducted by suspending the compound represented by the formula (12) in ethanol and dropping thionyl chloride slowly while cooling followed by stirring at room temperature.
- the compound represented by the formula (12), corresponding primary or secondary amine, HOBt (Advanced ChemTech Corp., USA) and triethylamine are dissolved in a proper solvent (for example, amide such as dimethylformamide or dimethylacetamide), which does not influence badly on the reaction.
- a proper solvent for example, amide such as dimethylformamide or dimethylacetamide
- a proper solvent for example, amide such as dimethylformamide or dimethylacetamide, or halogen-based solvents such as dichloromethane
- Preparation can be conducted by dissolving the compounds represented by the formula (9) and (11) to (14) in a proper solvent (for example, nitrile such as acetonitrile), which does not influence badly on the reaction, and adding the solution prepared by dissolving a triphenyltin hydride (Aldrich, USA) in a proper solvent (for example, aromatic hydrocarbon such as benzene, toluene or xylene), which does not influence badly on the reaction, to the above solvent, followed by reflux.
- a proper solvent for example, nitrile such as acetonitrile
- a proper solvent for example, aromatic hydrocarbon such as benzene, toluene or xylene
- the compound represented by the formula (4) can be dissolved in a proper solvent, and may exist as it is or as a reduced type represented by the following formula (15) or their mixture in the solvent:
- the compounds according to the present invention or salts thereof, which are obtained in such the way, can be isolated and purified by an ordinary separation means such as recrystallization, distillation or chromatography.
- an ordinary separation means such as recrystallization, distillation or chromatography.
- the compound according to the present invention can be converted to a salt thereof by a publicly known method or similar methods.
- the compound can be converted to a free form or other salts by a publicly known method or similar methods.
- the compound or the salt thereof may have an asymmetric carbon.
- the compound is obtained as an optically active mixture (racemic compound), it can be separated into each optical activity by an ordinary optical dividing means.
- a usable concentration of the differentiation inhibiting agent according to the present invention is preferably ranges from 0.1 ng/mL to 1 mg/mL, more preferably from 10 ng/mL to 100 ⁇ g/mL, particularly preferably from 100 ng/mL to 10 ⁇ g/mL.
- the differentiation inhibiting agent according to the present invention comprises a low molecular weight compound, particularly a tetrahydroisoquinoline derivative, which keeps undifferentiation of the embryonic stem cell without activation of STAT3 (signal transducer and activator of transcription 3).
- STAT3 signal transducer and activator of transcription 3
- Undifferentiation of the embryonic stem cell of a specific mouse line is maintained by LIF regardless of the presence or absence of the feeder cell composed of fibroblast cell derived from a mouse fetus. It has been known that the LIF transmits a signal to a downstream through activation of STAT3 (Matsuda et al., EMBO Journal, 18: 15: p 4261, 1999).
- the differentiation inhibiting agent according to the present invention comprises a low molecular weight compound which keeps undifferentiation of the embryonic stem cell without activation of STAT3.
- the differentiation inhibiting agent comprises a low molecular weight compound having the activity of keeping undifferentiation state of the embryonic stem cell by an action different from the action of the LIF.
- the Nanog gene was identified (Mitsui et al., Cell 113: p 631, 2003, Chambers et al., Cell 113: p 643, 2003).
- the presence of the Nanog gene was found from a mouse and a human.
- expression of the Nanog gene is suppressed by gene destruction, the totipotency of the embryonic stem cell is lost and, in contrast, when the Nanog gene is strongly expressed to increase an expression level, undifferentiation of the embryonic stem cell can be maintained even with the absence of LIF.
- a substance e.g., a low molecular weight compound, enabling increase in the expression level of the Nanog gene, can be used for maintaining undifferentiation of the embryonic stem cell, namely, for culturing the totipotent embryonic stem cell.
- the high expression of the Nanog gene does not activate STAT3 and, therefore, the Nanog gene keeps undifferentiation of the embryonic stem cell independently on LIF and STAT3. That is, it is suggested that a substance, e.g., a low molecular weight compound, enabling increase in the expression level of the Nanog gene, can be used for culturing the embryonic stem cell in which the effect of maintaining undifferentiation by LIF is not observed.
- a substance e.g., a low molecular weight compound, enabling increase in the expression level of the Nanog gene
- the differentiation inhibiting agent according to the present invention comprises a low molecular weight compound which increases the expression level of the Nanog gene.
- the differentiation inhibiting agent according to the present invention comprises a low molecular weight compound exerting the ability of keeping undifferentiation of the embryonic stem cell through the increase in the expression level of the Nanog gene.
- the differentiation inhibiting agent according to the present invention comprises a low molecular weight compound having the activity of keeping a cell in undifferentiation state without the STAT3 route.
- the differentiation inhibiting agent according to the present invention can be used by adding to an any basic culture medium for mammal cell culture, which is a basic medium for animal cell culture.
- the basic media for animal cell culture include Dulbecco's modified Eagle medium (DMEM), knockout DMEM, Glasgow MEM (GMEM), RPMI1640 and IMDM (these are Invitrogen Corp., USA made), but are not restricted to these examples.
- One embodiment of the cell culture medium is Dulbecco's modified Eagle medium (DMEM).
- these basic media can be used by adding with proteins involving in cell proliferation and differentiation regulation such as serum or a serum alternate, various kinds of growth factors and cytokines. Further, any compound may be added.
- Serum may be any serum or serum-based solution to supply a nutrient effective for proliferation and maintaining survival of the stem cell and the embryonic stem cell.
- examples of such serum include fetal calf serum (FCS), calf serum (CS), and horse serum (HS).
- FCS fetal calf serum
- CS calf serum
- HS horse serum
- the usable serum replacements include those known to those skilled in the art, proteins, amino acids, lipids, vitamins, and the like independently or in combination of them.
- Proteins include insulin, transferrin, albumin, peptone, FGF (Fibroblast Growth Factor), EGF (Epithelial Growth Factor) and the like
- amino acids include arginine, cysteine, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophane, tyrosine, valine and the like
- vitamins include pantothenic acid, choline, folic acid, inositol, nicotinic acid amide, riboflavin, thiamine, pyridoxine and the like, however, restriction is not applied to these compounds.
- serum is bovine fetus serum.
- bovine fetus serum is provided with a concentration between about 25% and about 1%.
- concentration of bovine fetus serum in the cell culture medium is 15%.
- the serum replacement is knockout serum replacement: KSR (Invitrogen Corp. USA made).
- the cell growth factors which can be added include a hepatocyte growth factor (HGF), epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin-like growth factor (IGF), nerve growth factor (NGF), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), transforming growth factor (TGF), bone morphogenetic protein (BMP), stem cell factor (SCF), Wnt, and the like, however, restriction is not applied to these compounds.
- the cytokines which can be added include interleukin (IL), granulocyte-macrophage colony stimulating factor (GM-CSF), and the like, however, restriction is not applied to these compounds. Further, differentiation regulation factor such as LIF and notch ligand can be added.
- the compound to be added is not specially restricted and may be an agonist or an antagonist to any protein and, also, may be an any phosphorylation inhibitor.
- PD98059 Cell Signaling Technology Corp. made
- 6-bromoindirubin-3oxim is provided.
- Cell culture medium also contains an antioxidant (a reductant) (for instance, ⁇ -mercaptoethanol).
- a reductant for instance, ⁇ -mercaptoethanol
- ⁇ -mercaptoethanol has a concentration of about 0.1 mM.
- Other antioxidants for instance, monothioglycerol or dithiothreitol (DTT) independently or in combination
- DTT dithiothreitol
- the differentiation inhibiting agent according to the present invention and the active ingredient thereof can be used by accompanying any culture medium material or by immobilizing it to the culture medium material.
- a porous material can be used.
- the porous material is the material having many fine pores and is not specially restricted in a kind, thickness, shape, and size of the material.
- the kind of the material may be an organic material, an inorganic material, and a complex material composed of an organic material and an inorganic material.
- the shape of the porous material may be any forms including flat plate, globular, rod-like, fibrous and hollow, and, for example, includes a film, sheet, membrane, board, unwoven fabric, filter paper, sponge, cloth, knitted fabric, lump, thread, hollow tube and particle.
- the unwoven fabric is more preferable in consideration of an easily regulatable pore size to support cells for allowing 3-dimensional culture and easy and low cost preparation of the material.
- the pore size of the porous material is not specially restricted, however, in consideration of 3-dimensional support of cells, an average pore size is preferably between 0.1 ⁇ m and 100 ⁇ m and further preferably between 1 ⁇ m and 50 ⁇ m.
- a fiber diameter is not specially restricted, however, 0.03 denier or smaller is preferable.
- the porous material as described above may be subjected to surface coating treatment with a high polymer.
- the high polymer is the substance that is constructed by linking linearly, squarely, or cubically 1 or more species of monomers being repeating constitutional units and that has a some-hundred molecular weight.
- the high polymer is classified into 3 major categories: natural high polymer, semisynthesized high polymer, and synthesized high polymer.
- any high polymers can be used.
- the natural high polymer includes mica, asbestos, graphite, diamond, starch, cellulose, saccharides such as alginic acid, and proteins such as gelatin, fibronectin, fibrinogen, laminin, and collagen.
- the semisynthesized high polymer includes glass, cellulose nitrate, cellulose acetate, rubber hydrochloride, and carboxymethyl cellulose.
- the synthesized high polymer includes polyphosphonitrile chloride, polyethylene, polyvinyl chloride, polyamide, polyethylene terephthalate, polysulfon, polyacrylonitrile, polyvinyl alcohol, polymethyl methacrylate, polyhydroxyethyl methacrylate, polydimethylaminoethyl methacrylate, and a copolymer, which is composed of 2 or more types of synthesized monomers, represented by the copolymer prepared by hydroxyethyl methacrylate and dimethylaminoethyl methacrylate.
- the culture medium material is gelatin.
- Matrigel (BD Bioscience Corp. made.) is used.
- a method and an apparatus for separation of the stem cell or the embryonic stem cell from a population of a plurality of different cells to carry out culturing can be provided by using the culture medium material, to which the differentiation inhibiting agent according to the present invention has been immobilized, as a cell-capturing material.
- a culture method of the stem cell or the embryonic stem cell wherein the stem cell or the embryonic stem cell and a cell-containing liquid containing cells, which should be removed, are introduced into a container in which the cell-capturing material of the culture medium material such as the porous material (on which the differentiation inhibiting agent according to the present invention has been immobilized) is filled, the stem cell or the embryonic stem cell is captured by the cell-capturing material, and, after the cells, which should be removed, are lead out from the container, the whole of the cell-containing solution with the container is cultured; and a cell-culturing apparatus, wherein the cell-capturing material of the culture medium material, on which the differentiation inhibiting agent according to the present invention is immobilized, is filled in the container, is provided, the cell-culturing apparatus being characterized in that the cell-capturing material as described above can be used as a support for cell culture and the container can be used for cell culture.
- the cells which should be removed, are all cells other than the stem cells or the embryonic stem cells. In addition, cells which were differentiated from the stem cells or the embryonic stem cells and lost multipotentcy, are also included in this cell group.
- the cell-containing liquid to be introduced into the cell-capturing material is satisfied by any cell liquid containing the stem cells or the embryonic stem cells and, as the example, includes blood, marrow, fragment tissue liquid, or a culture solution of the stem cells or the embryonic stem cells.
- the present invention relates to a method for proliferating the stem cells or the embryonic stem cells.
- a cultured product of the stem cells or the embryonic stem cells proliferated by using the differentiation inhibiting agent according to the present invention can be provided.
- Cells cultured by using the differentiation inhibiting agent according to the present invention includes all the stem cells or the embryonic stem cells which can be obtained by using the publicly known method and material.
- the stem cell includes, as an example, the stem cell available by the following publicly known method.
- a marrow cell (“Marrow Transplantation Guide” by H. J. Deeg, H. G Klingemann, G L. Phillips, translated in Japanese by Sinpei Kasakura), a marrow stem cell (Osawa et al., Science 273: p 242-245, 1996, Goodell et al., J. E. Med.
- the embryonic stem cells to be cultured can be obtained by using the following publicly known method and material.
- Murine embryonic stem cell Evans et al., Nature 292: p 154, 1981
- bovine ES cell Schellander et al., Theriogenology 31: p 15-17, 1989, swine ES cell: Strojek et al., Theriogenology 33: p 901, 1990
- sheep ES cell Handyside, Roux's Arch. Dev. Biol. 196: p 185, 1987
- hamster ES cell Doetschman et al., Dev. Biol. 127: p 224, 1988
- rhesus monkey ES cell Thomson et al., Proc.
- mouse embryonic stem cell (129SV and C57/BL6) can be obtained from Dai Nippon Seiyaku k.k.
- the differentiation inhibiting agent provided according to the present invention can be used for all the stem cells and the embryonic stem cells, and is desirably used for the stem cells and the embryonic stem cells of mammals and more preferably used for the stem cells and the embryonic stem cells of primates.
- Cells and embryonic stem cells which have been once isolated, can be cultured in the undifferentiated state by using the differentiation inhibiting agent of the present invention.
- the degree of the undifferentiated state of the stem cell, preferably the embryonic stem cell, cultured by using the differentiation inhibiting agent of the present invention can be confirmed by measuring an alkaline phosphatase (ALP) activity existing on a cell membrane of the stem cell. It is known that in an undifferentiated embryonic stem cell, the ALP activity is kept and, when the cell is differentiated, decreases (Williams et al., Nature 336: p 684, 1988, Thomson et al., Science 282: p 1145, 1998).
- the alkaline phosphatase (ALP) activity is detected by methods including a staining method by using an insoluble substrate or a spectrophotometric method by using a water-soluble substrate.
- the ALP activity can be quantified by the spectrophotometric method.
- An alkaline solution of paranitrophenylphosphate (pNPP) is added to a cell on a culture dish.
- pNPP is hydrolyzed by ALP present on the cell membrane to produce paranitrophenol.
- Measuring an absorbance of the produced solution at 405 nm enables quantification of alkaline phosphatase activity.
- Measuring the ALP activity of the embryonic stem cell cultured by adding the differentiation inhibiting agent of the present invention on the basis of the method described in Example 1 (5) shows that this cell has significantly higher ALP activity than that of a control embryonic stem cell cultured by using a culture medium lacking the differentiation inhibiting agent. This means that the differentiation inhibiting agent of the present invention allows the cells to proliferate while keeping the undifferentiated state of the embryonic stem cell.
- the ALP activity can also be detected by ALP staining method.
- a reaction solution containing a phosphate ester salt and a diazonium salt as the substrate are added to cells on a culture dish.
- the phosphate ester salt is hydrolyzed by alkaline phosphatase present on the cell membrane and, subsequently, a coupling reaction with the diazonium salt produces an azo pigment resulting in sedimentation of the pigment in an ALP active site.
- Counting number of stained colonies enables quantification of the ALP activity of the cell to allow quantifying the degree of undifferentiation of the cell.
- ALP staining of the embryonic stem cell cultured by using the differentiation inhibiting agent of the present invention on the basis of the method described in Example 1 (6) shows that this cell has significantly higher ALP activity than that of a control cell cultured by using a culture medium lacking the differentiation inhibiting agent. This means that the differentiation inhibiting agent of the present invention allows the cell to proliferate while keeping the undifferentiated state of the embryonic stem cell.
- the degree of undifferentiation of the embryonic stem cell can be known by measuring the expression level of the Oct-3/4 gene.
- the Oct-3/4 gene is a transcription factor belonging to a POU family, and is expressed specifically in the undifferentiated state in the embryonic stem cell and an embryonic cancer cell (EC cell) (Okamoto et al., Cell 60: p 461, 1990) and is expressed only in an undifferentiated cell line (Scholer, Trends Genet 7: p 323, 1991).
- EC cell embryonic cancer cell
- homozygous mice of which Oct-3/4 gene has been disrupted stops development at the blastodermic vesicle stage.
- the Oct-3/4 gene has an important function for keeping the undifferentiated state (Nichols et al., Cell 95: p 379, 1998).
- an over expression of the Oct-3/4 gene promotes differentiation of the embryonic stem cell (Niwa et al., Nat. Genet. 24: p 372, 2000). Therefore, it is important to keep the expression level of the Oct-3/4 in a specific range to maintain the undifferentiated state.
- a quantitative PCR polymerase chain reaction
- a real time PCR method is used to enable a convenient and reliable quantitative measurement having a wide dynamic range.
- the real time PCR technique includes the method by using a TaqMan probe using ABIPRISM7700TM (Applied Biosystems) and the method by using LightCyclerTM (Ropche Diagnostics). Particularly in the latter case, in a high rate reaction cycle in which a temperature cycle of PCR is completed for some 10 minutes, a change of an amplified amount of a DNA synthesized for every cycle can be detected in a real time.
- DNA detection method of the real time PCR method includes 4 methods using a DNA-binding pigment (intercalator), a hybridization probe (kissing probe), TaqMan probe, or Sunrise Uniprimer (molecular beacon).
- the expression level of the Oct-3/4 gene can be analyzed by using a DNA-binding pigment such as SYBR GreenI.
- SYBR GreenI is a binding pigment specific to a double strand of the DNA and, when bound to a double strand, an inherent fluorescence intensity is reinforced. By adding SYBR GreenI at the PCR reaction and measuring the fluorescence intensity at the end of each cycle of an elongation reaction, the increase in a PCR product can be detected.
- a primer is designed by using a commercialized gene analysis software on the basis of a sequence of the Oct-3/4 gene. SYBR GreenI detects a nonspecific product and, thus, requires designing an optimal primer.
- Required designing standards are a length of an oligomer, a base composition of the sequence, a GC content, and a Tm value.
- PCR aims to know the amount of a target DNA for a specific amount of a sample. For this purpose, an evaluation is required for the sample amount first added to a reaction system. In this case, measuring other DNA than the target DNA as an internal standard reflecting the sample amount enables to correct the sample amount first added to the reaction system.
- the internal standard used for correction of the sample amount can be a house keeping gene, ordinarily, of which expression level is believed to show no difference between tissues.
- the internal standard includes genes of glyceraldehydes phosphate dehydrogenase (GAPDH) being a major enzyme in a glycolysis system, ⁇ -actin or ⁇ -actin being a compositional component of a cell skeleton, and S26 being a compositional protein of a ribosome.
- GPDH glyceraldehydes phosphate dehydrogenase
- An expression level of the Oct-3/4 gene can be determined for the cell exposed to the differentiation inhibiting agent of the present invention.
- the compound, which has the activity capable of keeping significantly the expression level of Oct-3/4 gene as compared with the expression level of Oct-3/4 gene of a control cell which has not been exposed to the differentiation inhibiting agent of the present invention, that is, which has been differentiated and induced from the embryonic stem cell, is regarded as the differentiation inhibiting agent which maintains undifferentiation of the embryonic stem cell.
- Still further another method for screening an optimized culture medium material for keeping undifferentiation of the embryonic stem cell includes a method for detecting such antigen as Stage Specific Embryonic Antigen (hereafter SSEA)-1, SSEA-3, and SSEA-4 which are expressed specifically in undifferentiated cells (Smith et al., Nature 336: p 688, 1988, Solter et al., Proc. Natl. Acad. Sci. U.S.A 75: p 5565, 1978, and Kannagi et al., EMBO J. 2: p 2355, 1983).
- SSEA Stage Specific Embryonic Antigen
- a surface antigen such as SSEA-1 can be labeled by incubating together with a specific antibody (primary antibody) recognizing the antigen and further incubating together with a second antibody (secondary antibody) bound to such reporter as a fluorescence labeling substance.
- This operation makes the cell expressing the target antigen fluorescent.
- the labeled cell can be counted and collected separately by employing such a standard method as flow cytometry. Following this step, numbers of labeled and nonlabeled cells can be compared to determine an effect of the target culture medium material.
- the cell following exposure to a marker antibody of the nonlabeled cell surface, the cell can be exposed to the second antibody specific to an anti-cell surface antigen antibody (for example, anti-SSEA-1 antibody) in ELISA (enzyme-linked immunosorbent assay) manner, and number of cells expressing a desired surface antigen can be quantified by colorimetry or fluorescence measurement.
- an anti-cell surface antigen antibody for example, anti-SSEA-1 antibody
- ELISA enzyme-linked immunosorbent assay
- the improved differentiation inhibiting agent, culture method, and culture liquid for proliferation of the stem cells or the embryonic stem cells which are provided according to the present invention, are expected to be applied to all techniques for which the stem cells or the embryonic stem cells are useful.
- Cells produced by using the differentiation inhibiting agent, culture method, and culture liquid according to the present invention can be used, after differentiation thereof, for cell transplantation and artificial tissue construction accompanying with the use of an artificial support tissue to use for in vivo transplantation and an artificial organ.
- Using for cell transplantation therapy and tissue engineering of the stem cell can solve some problems in transplantation therapy, which includes conventional autotransplantation, such as tissue deficit after a transplanting piece is resected from a donor and shortage of the donor.
- the cell and tissue cultured for transplantation are used for returning to the identical person from whom the cell and tissue were collected, and for transplanting into other person, for medical treatment, and the cell and tissue of the present invention can be used for both purposes.
- the differentiation inhibiting agent of the present invention, the culture method using the inhibiting agent, and the culture product of a natural and a modified stem cell, preferably embryonic stem cell, obtained by using the culture liquid containing the inhibiting agent is used for monitoring the stem cell, preferably embryonic stem cell or for screening a substance which improving the collection of the stem cell.
- the substance presumably inducing differentiation of the stem cell or the embryonic stem cell can be added to a cell culture product proliferated by using the method as described above.
- a substance inducible of differentiation into a triploblastic lines is identified as an embryonic stem cell differentiation-inducing factor.
- the differentiation inhibiting agent and/or compound of the present invention or the salt thereof has an excellent stem cell undifferentiation-maintaining and proliferating abilities and, hence, can be used as a remedy for the tissue and the organ damaged by a disease or an injury.
- Targeted diseases include, for example, burn, intractable skin ulcer, bedsore, hyperplastic scar, birthmark, and tattoo and the like, which are related to a skin; fracture, osteoporosis and the like, which are related to a bone; osteoarthritis, chronic rheumatism, hernia of intervertebral disk, apophysitis, sport damage, which are related to a cartilage; Parkinson's disease, Huntington's disease, Alzheimer's disease, break of a nerve of limb caused by an injury, damage caused by head and neck surgery or thoracic surgery, facial nerve palsy, phrenic nerve damage, intrapelvic nerve damage and the like, which are related to a nerve; alveolar bone damage and anodontia caused by periodontal disease or pyorrhea and the like, which are related to a tooth; male pattern alopecia, which is related to a hair; birth defect, endothelial cell decompensation, opacity caused by cornea infection, cornea degeneration,
- the differentiation inhibiting agent and/or compound of the present invention can be administered orally or parenterally as preventive and/or remedy for diseases as described above; and is orally administered normally in a solid form such as tablet, capsule, granule and powder through blending with a pharmaceutically acceptable carrier, or is parenterally administered intravenously, subcutaneously or intramuscularly as an injection, suppository, or sublingual tablet. Further, sublingual, subcutaneous and intramuscular administration may be conducted as a sustained-release preparation such as a sublingual tablet and a microcapsule.
- a daily dose depends on a degree of a symptom; an age, sexuality, body weight, difference in sensitivity of an administrative subject; time and interval of administration, property, compounding and kind of a medicine preparation; a kind of the active ingredient, however, are not restricted especially.
- the dose for using in animal husbandry and fisheries fields follows the above standard and, for a 1 kg body weight of a target organism, about 0.01-30 mg or preferably about 0.1-10 mg is normally given in 1 to 3 times a day.
- the content of the compound of the present invention contained in a pharmaceutical composition ranges from about 0.01-100% by weight of the whole composition.
- various kinds of organic or inorganic carrier substances conventionally used as a drug preparation materials are used and compounded as a vehicle, lubricant, binder, disintegrator in a solid preparation; and a solvent, solubilizer, suspending agent, isotonizing agent, buffering agent, soothing agent and the like in a liquid preparation.
- a solvent, solubilizer, suspending agent, isotonizing agent, buffering agent, soothing agent and the like in a liquid preparation.
- preparation additives as an antiseptic agent, antioxidant, colorant, edulcorant and the like can also be used.
- the vehicle include, for example, lactose, saccharose, D-mannitol, starch, crystallized cellulose, light anhydrous silicic acid, and the like.
- lubricant examples include, for example, magnesium stearate, calcium stearate, talc, colloid silica, and the like.
- binder examples include, for example, crystallized cellulose, saccharose, D-mannitol, dextrin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, polyvinyl pyrolidone, and the like.
- disintegrator examples include, for example, starch, carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, sodium carboxymethyl starch, and the like.
- solvent examples include, for example, water for injection, alcohol, propylene glycol, macrogol, sesame oil, corn oil, and the like.
- solubilizer examples include, for example, polyethylene glycol, propylene glycol, D-mannitol, benzyl benzoate, ethanol, tris amino methane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, and the like.
- the suspending agent include, for example, surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride and glycerin monostearate, hydrophilic high polymer such as polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and the like.
- surfactants such as stearyl triethanolamine, sodium lauryl sulfate, lauryl aminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride and glycerin monostearate
- hydrophilic high polymer such as polyvinyl alcohol, polyvinyl pyrrolidone, sodium carboxymethyl cellulose, methyl cellulose, hydroxymethyl cellulose, hydroxyethyl
- Preferable examples of the isotonizing agent include, for example, sodium chloride, glycerin, D-mannitol and the like.
- Preferable examples of the buffering agent include, for example, a buffer liquid of phosphate, acetate, carbonate, citrate and the like.
- Preferable examples of the soothing agent include, for example, benzyl alcohol and the like.
- Preferable examples of the antiseptic agent include, for example, paraoxybenzoic acid esters, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
- Preferable examples of the antioxidant include, for example, sulfite, ascorbic acid and the like.
- the suspending agent, solubilizer, stabilizer, isotonizing agent, preservative or the like is added to the differentiation inhibiting agent and/or compound of the present invention, so as to prepare a venous, subcutaneous or intramuscular injection by a publicly known method.
- a freeze-dried product can be prepared by a publicly known method.
- the compound of the present invention can be safely administered orally or parenterally in an independent form or in the form, which is blended with a proper pharmacologically acceptable carrier, vehicle or diluent, as a pharmaceutical composition.
- the pharmaceutical composition as described above includes an orally-administering agent (example: powder, granule, capsule, tablet), a parenterally-administering agent [example: an injection, a drip, an external using agent (example: a nasal preparation, a percutaneous preparation and the like), and a suppository (example: a rectum suppository, a vaginal suppository and the like)].
- an orally-administering agent example: powder, granule, capsule, tablet
- a parenterally-administering agent example: an injection, a drip, an external using agent
- a suppository example: a rectum suppository, a vaginal suppository and the like
- the differentiation inhibiting agent and/or compound of the present invention can be made in an injection by forming as an aqueous injection by blending with a dispersant (example: Tween 80 (Atlas Powder Corp., USA made), HCO60 (Nikkou Chemicals made), polyethylene glycol, carboxymethyl cellulose, sodium alginate and the like), a preservative (example: methyl paraben, propyl paraben, benzyl alcohol and the like), an isotonizing agent (example: sodium chloride, mannitol, sorbitol, glucose and the like), or an oily injection prepared by dissolving, suspending, or emulsifying in a plant oil such as olive oil, sesame oil, cotton seed oil, corn oil or the like, or propylene glycol.
- a dispersant example: Tween 80 (Atlas Powder Corp., USA made), HCO60 (Nikkou Chemicals made), polyethylene glycol, carboxymethyl
- the oral preparation can be manufactured by adding the differentiation inhibiting agent and/or compound of the present invention to, for example, a vehicle (for example, lactose, saccharose, starch or the like), a disintegrator (starch, calcium carbonate or the like), a binder (for example, starch, gum acacia, carboxymethyl cellulose, polyvinyl pyrrolidone, hydroxypropyl cellulose or the like), and a lubricant (for example, talc, magnesium stearate, polyethylene glycol 6000 or the like) to be subjected to compression molding followed by, when required, taste masking and coating for the purpose of an enteric preparation and a prolonged action by the method known per se.
- a vehicle for example, lactose, saccharose, starch or the like
- a disintegrator starch, calcium carbonate or the like
- a binder for example, starch, gum acacia, carboxymethyl cellulose, polyvinyl pyrrolidone, hydroxy
- the usable coating agent includes, for example, hydroxypropylmethyl cellulose, ethyl cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, polyoxy ethylene glycol, Tween 80, Pluronic F68, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate, hydroxymethylcellulose acetate succinate, Eudragit (Rohm Pharma made, Germany: methacrylic acid-acrylic acid copolymer), or a pigment (example; colcothar, titanium dioxide or the like) after the method known per se.
- an intermediate phase can be made between an enteric phase and a drug-containing phase by a method publicly known per se in order to separate both these phases.
- the differentiation inhibiting agent and/or compound of the present invention can be made in a solid, semisolid or liquid drug for the external use according to a publicly known method.
- the usable solid form as described above includes a powder composition of the intact compound of the present invention or that prepared by adding and blending the vehicle (example: glycol, mannitol, starch, finely crystallized cellulose or the like), thickener (example: natural rubbers, cellulose derivatives, acrylic acid polymer or the like).
- the liquid form is prepared as an oily or aqueous suspension almost similar to the injection.
- the semisolid form is preferably an oily or aqueous gelatinous agent or ointment-like product.
- the compound of the present invention can be prepared as an oily or aqueous solid, semisolid or liquid suppository by a method publicly known per se.
- An oily base used for the composition as described above includes, for example, a glyceride of a higher fatty acid (example: cacao butter, Witepsols (Dynamite Nobel Corp, Germany,) or the like) or a medium fatty acid (example: Miglyols (Dynamite Nobel Corp, Germany,) or the like), or plant oil (example: sesame oil, soy bean oil, cotton seed oil or the like).
- the aqueous medium includes, for example, polyethylene glycols, propylene glycol
- the aqueous gelatinous medium includes, for example, natural rubbers, cellulose derivatives, vinyl polymers, acrylic acid derivatives or the like.
- the prodrugs of the compounds (9) and (10) are compounds which are converted to the compound (9) or (10) having the stem cell proliferation action by an in vivo metabolic reaction by an enzyme and a gastric acid.
- the prodrug of the compounds (9) and (10) include: when the compounds (9) and (10) have an amino group, the compound produced by acylation, alkylation or phosphorylation of the amino group (example: the compounds produced by bonding an eicosanoyl, aranyl, pentylaminocarbonyl, (5-methyl-2-oxo-1,3-dioxolene-4-yl)methoxycarbonyl, tetrahydrofuranyl, pyrrolidylmethyl, pivaloyloxymethyl or tert-butyl to the amino groups of the compounds (9) and (10)); when the compounds (9) and (10) have a carboxyl group, the compound produced by esterification or amidation of the carboxyl group (example: the compounds produced by eth
- the prodrugs of the compounds (9) and (10) may be those changeable to the compounds (9) and (10) according to a physiological condition, which have been described in “lyakuhin no Kaihatsu (Development of Drugs)” Vol. 7, Bunsi Sekkei: p 163-198, 1990, Hirokawa Syoten.
- the prodrugs of the compounds (9) and (10) may be themselves or the pharmacologically acceptable salt.
- Such the salt includes salts made from, when the prodrugs of the compounds (9) and (10) have an acidic group such as carboxyl group, inorganic base (example: alkali metals such as sodium and potassium, alkali earth metals such as calcium and magnesium, transition metals such as zinc, iron, copper, or the like) or organic base (example: organic amine such as trimethyl amine, triethyl amine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N,N′-dibenzylethylenediamine, or the like or basic amino acid such as arginine, lysine, ornithine, or the like).
- the salts made from inorganic acid and organic acid (example: hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, carbonic acid, bicarbonic acid, formic acid, acetic acid, propionic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid, or the like) or acid amino acid such as aspartic acid or glutamic acid are exemplified.
- the prodrugs of the compounds (9) and (10) may be either a hydrate or a nonhydrate.
- the compounds (9) and (10) may have 1 or 2 sites in the molecule capable of producing geometric isomers (cis-trans isomers) and the compound having the cis- and trans-isomers in an arbitrary proportion is included in the present invention.
- the compounds (10) may have 1 or more asymmetric carbons in the molecule and both of an R arrangement and S arrangement related to these asymmetric carbons are included in the present invention.
- the compounds (9) and (10) may be labeled with an isotope (example: 3 H or 14 C), or the like.
- the prodrugs of the compounds (9) and (10) may be those prepared by binding a polysaccharide (dextran, pluran, mannan, chitin, chitosan, or the like) with the compounds (9) and (10) in a reaction point which is an amino group, carboxyl group, hydroxyl group or the like.
- the prodrugs of the compounds (9) and (10) may be a complex prepared by inclusion in cyclodextrin (there are ⁇ form, ⁇ form and ⁇ form, however, preferably ⁇ or ⁇ form).
- room temperature described in the following examples represents a range from 0 to 30° C.
- % means a percent by weight unless otherwise stated.
- DMEM Dulbecco's modified Eagle medium
- DMEM Dulbecco's modified Eagle medium
- ESGRO contains a mouse LIF as the active ingredient.
- an assay medium was prepared by excluding ESGRO from the ES cell culture medium as described above.
- a mouse embryonic stem cell line D3ES cell (available from Rolf Kemler, Max Planck Institut fur Immunbiologie, Stuheweg 51, D-79108, Freiburg, Germany) was seeded on a fibroblast cell feeder layer with a 6 cm diameter and cultured and proliferated using 5 mL-ES culture medium at 37° C. in 5% CO 2 in the incubator for 2 days.
- trypsin solution Invitrogen Corp. made, 15090-046
- the medium containing the floating cells was transferred to a 50 mL-sterilized tube, centrifuged at 1000 rpm for about 5 minutes by using a table centrifuge, and then, the supernatant was removed followed by suspending again in a 5 mL-ES cell assay medium to obtain the ES cell.
- D3ES cell obtained by the preparation of the mouse ES cell as described in (3) above 3 ⁇ 10 2 to 1 ⁇ 10 3 cells per well was seeded in 90 ml of the ES cell assay medium in a well of a 96-well cell culture dish (Falcon Corp. made, Cat. No. 3072, USA) coated previously with a 0.1% aqueous gelatin solution.
- a 10 ⁇ l of the differentiation inhibiting agent (A,B,C,D,E,F: A to D were ASINEX Corp. ( Russia) made and E to F were purchased from PHARMEKS Corp.
- the medium was removed by sucking from individual wells of the ES cells cultured for 7 days according to the method described in ES cell differentiation inhibiting agent assay 1 as described above, and the cells were washed once with 100 ⁇ l of phosphate buffered saline (PBS) and, then, p-NPP 100 ⁇ l was added to each well to left stand at room temperature for 10 minutes. 12.5 ⁇ L of 8 M sodium hydroxide aqueous solution was added to each well to stop the reaction. An absorbance at 405 nm (O.D.405) and absorbance at 690 nm (O.D.690) were measured by using a spectrophotometer (Molecular Devices Corp. made, type: SPECTRA MAX190), and a value calculated by O.D.405-O.D.690 was determined as the alkaline phosphatase activity.
- FIG. 3 shows the graphed result of the quantification.
- the differentiation inhibiting agent, the compound A to F, of the present invention increased significantly the alkaline phosphatase activity in comparison with the control, DMSO (0.1%). From this, it is known that the differentiation inhibiting agent of the present invention supported the culture of undifferentiated ES cells.
- the ES cells were stained by using an alkaline phosphatase kit (SIGMA Diagnostic Corp. made, Cat. No. 86-R).
- the medium was removed by sucking from individual wells of the ES cells cultured by the method described in (4) ES cell differentiation inhibiting agent assay 1 as described above, and the cells were washed once with 2 mL of phosphate buffered saline (PBS), and then 2 mL of a cell-fixing solution (25 mL citric acid solution (SIGMA Corp. made, Cat. No. 91-5), 65 mL acetone, 8 mL 37% formaldehyde) was added to each well to be left stand at room temperature for 30 seconds.
- PBS phosphate buffered saline
- a cell-fixing solution 25 mL citric acid solution (SIGMA Corp. made, Cat. No. 91-5)
- the fixing solution was removed by sucking, and 2-mL of deionized water was added to individual wells and left stand at room temperature for 45 seconds.
- the deionized water was removed by sucking and, then, a 2-mL of alkaline phosphatase staining solution (1 mL sodium nitrite solution, 1 mL Fast Red Violet LB salt solution, 1 mL naphthol AS-BI alkaline solution, 45 mL distilled water) was added to each well and left stand at room temperature for 15 minutes followed by removal of the staining solution by sucking, and washing was carried out with 2 mL of deionized water.
- alkaline phosphatase staining solution (1 mL sodium nitrite solution, 1 mL Fast Red Violet LB salt solution, 1 mL naphthol AS-BI alkaline solution, 45 mL distilled water
- Staining images were compared among the ES cells cultured in the absence of ESGRO being a negative control, the ES cells cultured in the presence of ESGRO (1000 units/mL) being a positive control, and the ES cells cultured in the presence of the compound B (4 ⁇ g/mL) which is the differentiation inhibiting agent of the present invention (refer to FIG. 4 ).
- the ES cells cultured in presence of the compound B were, in comparison with the ES cells cultured in the absence of ESGRO, stained significantly more densely showing that the ES cells have a higher alkaline phosphatase activity.
- the differentiation inhibiting agent of the present invention allowed to form an undifferentiated colony equal to that of the ES cells cultured in the presence of ESGRO being the positive control. From this result, the differentiation inhibiting agent of the present invention supported strongly proliferation of the ES cells in the undifferentiated state.
- D3ES cells prepared by the method described in (3) preparation of a mouse ES cell of Example 1 1 ⁇ 10 5 cells in 500 ⁇ L ES medium were seeded in a well of a 24-well cell culture dish (Falcon Corp. made, Cat. No. 3047, USA) coated previously with a 0.1% aqueous gelatin solution, followed by culturing at 37° C. in 5% CO 2 incubator for 12 hours to 24 hours.
- a protocol attached to the product 0.9 ⁇ g per 1 well of pSTAT3-TA-Luc or pTA-Luc vector (Clontech Corp. made, USA) was transfected into the ES cells.
- 0.1 ⁇ g of an internal control, pRL-TK vector (Promega Corp. made, USA) was transfected at the same time for each well. Following culturing at 37° C. in 5% CO 2 incubator for 4 hours, the medium was sucked, and the cells were washed twice with PBS and, then, a 500 ⁇ L-ES assay medium was added to each well.
- D3ES cells prepared by the method described in (3) preparation of a mouse ES cell of Example 1 8 ⁇ 10 4 cells were seeded in a 10 cm-diameter cell culture dish coated previously with a 0.1% aqueous gelatin solution to make 10 mL of the ES cell assay medium.
- 1 mL of the differentiation inhibiting agent A to F which were dissolved in dimethylsulfoxide (DMSO) or culture medium or their mixture to make 40 ⁇ g/mL per each dish, or ESGRO, which was adjusted to make 10 4 unit/mL, was added, and culturing was carried out at 37° C. in 5% CO 2 incubator for 7 days.
- DMSO dimethylsulfoxide
- ESGRO which was adjusted to make 10 4 unit/mL
- RNA was extracted from the ES cells cultured by the method described in (1) ES cell differentiation inhibition assay 2 as described above, by using ISOGEN (K.K. Nippon Gene, Japan made) by the attached method.
- the medium was removed from the dish after the culture, the cells were washed twice with 10 mL of PBS, and dissolved in 1 mL of ISOGENE. After leaving stand at room temperature for 5 minutes, the solution was collected in a 1.5 mL Eppendorf tube. 0.2 mL of chloroform (Wako Pure Chemical Industries made) was added, shaken for 15 seconds and, then, left stand at room temperature for 2 or 3 minutes. The solution was centrifuged at 4° C.
- RNA 2 ⁇ g was used as a template to synthesize a cDNA according to the attached protocol by using Deoxyribonuclease I (Amplification Grade)(Invitrogen Corp. made), Oligo(dT)12-18 primer (Invitrogen Corp. made, 18418-012) and Omniscript reverse transcriptase (QIAGEN Corp. made).
- a reaction solution was prepared by adding 1 ⁇ L of 10 ⁇ DNaseI Reaction Buffer, 1 ⁇ L of 10 ⁇ DNaseI (all were made by Invitrogen Corp.) and distilled water to 2 ⁇ g of total RNA to make 10 ⁇ L in total, and the mixture was incubated at room temperature for 10 minutes.
- a portion of the synthesized cDNA obtained in such the way was diluted 5 folds with distilled water, and 2 ⁇ L of the solution was used as the template to conduct PCR by using Light Cycler-Fast Start DNA Master SYBR Green I Kit (Roche Diagnostics Corp. made) according to the attached protocol.
- the expression levels of the Oct-3/4 gene and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene as the internal standard were measured.
- sense primer OCT3 up SEQ ID No.: 1
- antisense primer Oct3 down SEQ ID No.: 2
- sense primer GAPDH up SEQ ID No.: 3
- antisense primer GAPDH down SEQ ID No.: 4
- composition of the PCR reaction solution for Oct-3/4 gene quantification 25 mM MgCl 2 1.6 ⁇ L 5 ⁇ M sense primer 1.0 ⁇ L 5 ⁇ M antisense primer 1.0 ⁇ L cDNA (5-fold dilution) 2.0 ⁇ L Light Cycler-Fast Start DNA Master 2.0 ⁇ L H 2 O 12.4 ⁇ L Total 20.0 ⁇ L
- the differentiation inhibiting agents (B, D and F) of the present invention maintain undifferentiation of the ES cell. From the result as described above, it was shown that, also from the expression level of the Oct-3/4 gene, the differentiation inhibiting agents B, D and F of the present invention keeps the undifferentiation state of the ES cell.
- D3ES cells prepared by the method described in (3) preparation of a mouse ES cell of Example 1 7.85 ⁇ 10 5 cells were seeded in a 10 cm-diameter cell culture dish coated previously with a 0.1% aqueous gelatin solution to make 10 mL of the ES cell assay medium.
- the differentiation inhibiting agent B of the present invention in the final concentration of 4 ⁇ g/mL or ESGRO in the final concentration of 1 ⁇ 10 3 unit/mL was added to each dish, and culturing was carried out at 37° C. in 5% CO 2 incubator for 1 day.
- the total RNA was extracted from the ES cell cultured by the method shown in (3) ES cell differentiation inhibition assay 3 as described above by using ISOGEN (K.K. Nippon Gene Corp. Japan made) by the attached method.
- the cell was collected in a 15 mL sterilized tube, centrifuged at 1,000 rpm for about 5 minutes by using the table centrifuge (TOMY SEIKO made) to make pellets. The supernatant was removed, the pellets were washed twice with 10 mL of PBS, and then, transferred to a 1.5 mL Eppendorf tube.
- the pellets were dissolved in 1 ml ISOGENE and left stand at room temperature for 5 minutes and, then, added with 0.2 mL of chloroform (Wako Pure Chemicals), shaken for 15 seconds, and left stand at room temperature for 2 or 3 minutes. Centrifugation was carried out at 4° C. at 10,000 rpm for 15 minutes by using the micro centrifuge (TOMY SEIKO made). 400 ⁇ L of the supernatant was transferred to a fresh 1.5 mL Eppendorf tube. 500 ⁇ L of isopropanol (Wako Pure Chemicals) was added and the mixture was left stand at room temperature for 10 minutes and, then, was centrifuged at 4° C. at 10,000 rpm for 10 minutes by using the micro centrifuge.
- the supernatant was removed and, then, 1 mL of a 70% ethanol aqueous solution was added. The mixture was shaken and then was centrifuged at 4° C. at 10,000 rpm for about 5 minutes by using the micro centrifuge. The supernatant was removed and the precipitation was dried and, then, dissolved in 30 ⁇ L of distilled water to obtain the total RNA solution.
- the cDNA was synthesized by using 2 ⁇ g of the total RNA obtained by such the way as the template, using DeoxyribonucleaseI (Amplification Grade) (Invitrogen Corp. made) and SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen Corp. made, 18080-051) by the attached protocol.
- 1 ⁇ L of 10 ⁇ DNaseI Reaction Buffer, 1 ⁇ L of 10 ⁇ DNaseI (all these were of Invitrogen Corp. made) were added to 2 ⁇ g of the total RNA to give the total volume of 10 ⁇ L by adding distilled water to prepare the reaction solution, and then incubation was carried out at room temperature for 10 minutes.
- PCR was conducted by diluting a portion of the synthetic cDNA thus obtained 5 folds with distilled water and using 2 ⁇ L of it as the template and also using Light Cycler-Fast Start DNA Master SYBR Green I Kit (Roche Diagnostics Corp. made) by the attached protocol.
- the expression level of the Nanog gene and the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene as the internal standard were measured.
- sense primer Nanog_up SEG ID No.: 5
- antisense primer Nanog_down SEQ ID No.: 6
- sense primer GAPDH_up SEQ ID No.: 3
- antisense primer GAPDH_down SEQ ID No.: 4
- the composition of the PCR reaction solution and the reaction condition will be each presented below.
- composition of the PCR reaction solution for the Nanog gene quantification 25 mM MgCl 2 2.4 ⁇ L 5 ⁇ M sense primer 1.0 ⁇ L 5 ⁇ M antisense primer 1.0 ⁇ L cDNA (5-fold dilution) 2.0 ⁇ L Light Cycler-Fast Start DNA Master 2.0 ⁇ L H 2 O 11.6 ⁇ L Total 20.0 ⁇ L
- the expression level of Nanog gene of the ES cells cultured in the presence of the differentiation inhibiting agents B of the present invention increased significantly in comparison with the ES cells cultured in the medium without the differentiation inhibiting agent and the ES cells cultured in the medium containing 1,000 units/mL of ESGRO ( FIG. 7 ).
- the differentiation inhibiting agents B of the present invention has the effect of maintaining undifferentiation of the ES cell.
- the cells cultured in (1) ES cell differentiation inhibition assay 2 as described above were washed twice with PBS, and were removed from the dish with a cell scraper. 300 ⁇ L of Hanks balanced salt solution (HBSS, Invitrogen Corp. made) containing 2% FBS was added to give 6 ⁇ 10 5 cells. 30 ⁇ L of MX-SSEA-1 antibody (Kyowa Medex Corp. made) diluted 50 folds with HBSS was added, and left stand for 40 minutes on ice. The cells were washed twice with HBSS (1 mL) and, then, dispersed again in HBSS (300 ⁇ L), and 30 ⁇ L of FITC-Goat anti Mouse IgM antibody (ZYMED Corp.
- HBSS Hanks balanced salt solution
- MX-SSEA-1 antibody Kyowa Medex Corp. made
- HBSS HBSS diluted 20 folds with HBSS was added and, then, left stand on ice for 30 minutes in shielded light.
- the cells were washed twice with HBSS (1 mL) and, then, dispersed again in HBSS (1 mL), added with 100 ⁇ L of 20 ⁇ g/mL PI solution (Dojindo Corp. made) to obtain a sample used for flow cytometry.
- the sample used for flow cytometry was measured after passed through a nylon mesh with a 100 ⁇ m pore size to eliminate a coagulated mass.
- a flow cytometer used was FACS Calibur (BECTON DICKINSON Corp. made) and software applied for collection and analysis of data of the measuring condition was CELL Quest (BECTON DICKINSON Corp. made).
- FIG. 8 An average fluorescence intensity per 1 cell, in other words, an SSEA-1 antigen expression intensity per 1 cell, of the cells cultured by adding each differentiation inhibiting agent, was increased significantly in comparison with the cells cultured in the medium without the differentiation inhibiting agent.
- the same experiment was carried out for the differentiation inhibiting agents A, C and E and the expression level of the SSEA-1 was significantly high as well.
- the differentiation inhibiting agents of the present invention maintain the undifferentiated ES cell.
- D3ES cells prepared by the method described in (3) preparation of a mouse ES cell of Example 1 3200 cells/well were seeded on a 96-well cell culture dish (Falcon Corp. made, Cat. No. 3072, USA) coated previously with a 0.1% aqueous gelatin solution to make 100 ⁇ L of the ES cell assay medium.
- a and j to m were purchased from IF LAB Ltd., Ukraine, b, c, f and n were from PHARMEKS Corp., Russia, d, e and o were from SPECS Corp., The Netherlands, g to i were from CHEMBRIDGE Corp., USA), which was dissolved in dimethylsulfoxide (DMSO) or water, or their mixture to make 0.4 to 40 ⁇ g/mL per each well, or ESGRO was added, and culturing was carried out at 37° C. in 5% CO 2 incubator for 4 days. The final concentration of DMSO in the culture medium was 0.1% or lower. On the other hand, to a control well was added only DMSO to make the final concentration 0.1%.
- the structures of the differentiation inhibiting agents a to o are presented in FIG. 9 .
- Alkaline phosphatase quantification 2 The alkaline phosphatase activity of the ES cell was quantified by using p-NITROPHENYLPHOSPHATE SOLUTION (MOSS Inc. made PRODUCT NO. NPPD-1000, USA; or SIGMA Corp. made A-3469, USA made) (hereafter p-NPP). The medium was removed by sucking from individual wells of the ES cells cultured for 4 days according to the method described in (1) ES cell differentiation inhibition assay 4 as described above, and the cells were washed once with 100 ⁇ L of phosphate buffered saline (PBS), and then 100 ⁇ L of p-NPP was added to each well to left stand at room temperature for 10 minutes.
- PBS phosphate buffered saline
- FIG. 10 shows the graphed result of the quantification.
- the differentiation inhibiting agents, the compounds a to o, of the present invention increased significantly the alkaline phosphatase activity in comparison with the control, DMSO (0.1%). From this, it is known that the differentiation inhibiting agent of the present invention supported the culture of the undifferentiated ES cells.
- D3ES cells prepared by the method described in (3) preparation of the mouse ES cell of Example 1 8 ⁇ 10 4 cells were seeded on a 10 cm-diameter cell culture dish coated previously with a 0.1% aqueous gelatin solution to make 10 mL of the ES cell assay medium.
- 1 mL of the differentiation inhibiting agent (a to o) of the present invention which was dissolved in dimethylsulfoxide (DMSO) or culture medium, or their mixture to make 40 ⁇ g/mL per each dish, or ESGRO was added, and culturing was carried out at 37° C. in 5% CO 2 incubator for 4 days.
- the final concentration of DMSO in the culture medium was 0.1% or lower.
- the cells cultured in (3) ES cell differentiation inhibition assay 5 as described above were washed twice with PBS, and were removed from the dish with a cell scraper.
- 300 ⁇ L of Hanks balanced salt solution (HBSS, Invitrogen Corp. made) containing 2% FBS was added to make cell number in 6 ⁇ 10 5 .
- 30 ⁇ Lof MX-SSEA-1 antibody (Kyowa Medex Corp. made) diluted 50 folds with HBSS was added and left stand for 40 minutes on ice.
- the antigen was washed twice with HBSS (1 mL) and, then, dispersed again in HBSS (300 ⁇ L), and 30 ⁇ L of FITC-Goat anti Mouse IgM antibody (ZYMED Corp.
- HBSS HBSS diluted 20 folds with HBSS was added and, then, left stand on ice for 30 minutes in shielded light.
- the cells were washed twice with HBSS (1 mL) and, then, dispersed again in HBSS (1 mL), added with 100 ⁇ L of 20 ⁇ g/mL PI solution (Dojindo Corp. made) to obtain the sample used for flow cytometry.
- the sample used for flow cytometry was measured after passed through the nylon mesh with the 100 ⁇ m pore size to eliminate the coagulated mass.
- the flow cytometer used was FACS Calibur (BECTON DICKINSON Corp. USA made) and software applied for collection and analysis of data of the measuring condition was CELL Quest (BECTON DICKINSON Corp. USA made).
- the result is shown in FIG. 11 .
- the average fluorescence intensity per 1 cell, in other words, the SSEA-1 antigen expression intensity per 1 cell, of the cells cultured by adding each differentiation inhibiting agent was increased significantly in comparison with the cells cultured in the medium without the differentiation inhibiting agent.
- the same experiment was carried out for the differentiation inhibiting agents b to o and the expression level of the SSEA-1 was significantly high as well. It was shown that the differentiation inhibiting agents of the present invention maintain the undifferentiated ES cells.
- D3ES cells prepared by the method described in (3) preparation of the ES cell of Example 1 1 ⁇ 10 5 cells were seeded on a 24-well cell culture dish (Falcon, Cat. No. 3047, USA) coated previously with a 0.1% aqueous gelatin solution to make the ES cell medium in 500 ⁇ L per 1 well, followed by culturing at 37° C. in 5% CO 2 incubator for 12 hours to 24 hours.
- a protocol attached to the product 0.9 ⁇ g/well of pSTAT3-TA-Luc or pTA-Luc vector (Clontech Corp. made, USA) was transfected into the ES cells.
- 0.1 ⁇ g of the internal control, pRL-TK vector (Promega Corp. made, USA) was transfected at the same time for each well. Following culturing at 37° C. in 5% CO 2 incubator for 4 hours, the medium was sucked and washed twice with PBS and, then, the 500 ⁇ L-ES assay medium was added to each well.
- ES cells prepared by the method described in (3) preparation of the mouse ES cell of Example 1 3x10 5 cells were seeded on a 6 cm-diameter cell culture dish coated previously with a 0.1% aqueous gelatin solution to make 4.5 mL of the ES cell assay medium.
- 0.5 mL of the differentiation inhibiting agent (A to F and a to o) of the present invention which was dissolved in dimethylsulfoxide (DMSO) or culture medium, or their mixture to make 10 to 40 ⁇ g/mL per each dish, or 10 4 units/mL of ESGRO was added.
- the final concentration of DMSO in the culture medium was 0.1% or lower.
- DMSO DMSO was made the final concentration in 0.1% by adding 0.5 mL of a 1% concentration solution diluted with the medium. Culturing was conducted at 37° C. in 5% CO 2 incubator for 7 to 30 days. The medium was replaced every day, and the cells were passaged to make 3 ⁇ 10 5 cells/dish for every 2 to 3 days.
- the alkaline phosphatase activity of the ES cells cultured for 7 or 30 days by using the differentiation inhibiting agents of the present invention was quantified by applying colony assay.
- 1 ⁇ 10 3 cells/l well were seeded on a 96-well cell culture dish (Falcon Corp. made, Cat. No. 3072, USA) coated previously with a 0.1% aqueous gelatin solution to make the ES cell assay medium in 90 ⁇ L/1 well.
- 10 ⁇ L of ESGRO diluted with the medium was added to each well to make 0 to 10 3 units/mL, and culturing was carried out at 37° C. in 5% CO 2 incubator for 4 days.
- the medium was removed by sucking from individual wells, and the cells were washed once with 100 ⁇ L of phosphate buffered saline (PBS), and then, 100 ⁇ L of p-NPP was added to each well to left stand at room temperature for 10 min. 12.5 ⁇ L of a 8 M sodium hydroxide aqueous solution was added to each well to stop the reaction.
- the absorbance at 405 nm (O.D.405) and absorbance at 690 nm (O.D.690) of the solution were measured by using the spectrophotometer (Molecular Devices Corp. made, type: SPECTRA MAX190), and the value calculated from O.D.405-O.D.690 was determined as the alkaline phosphatase activity.
- FIG. 13 shows the result of the quantification of the alkaline phosphatase of the ES cells subcultured for 30 days by adding the compound B.
- FIG. 14 shows the result of the quantification of the alkaline phosphatase of the ES cells subcultured in the medium without serum for 7 days by adding the compound f.
- the culture medium for a mouse feeder cell used for culturing cynomolgus monkey ES cells was prepared by adding respective factors to DMEM (Invitrogen Corp. made, 11960-044) in the final concentration shown below: 10% bovine fetus serum (Invitrogen Corp. made), 2 mM L-glutamine (Sigma G7513), 1 ⁇ penicillin/streptomycin solution (Sigma P0781).
- Gelatin (SIGMA Corp. made, Type A: from porcine ESkin, G2500) was dissolved in distilled water in 0.1% concentration, and 5 mL of the thus prepared 0.1% sterilized aqueous gelatin solution was added in a 6 cm-diameter cell culture dish, and then left stand at 37° C. for 30 minutes or longer.
- the aqueous gelatin solution was removed, and 2 ⁇ 10 6 mouse embryonic primary culture cell (Invitrogen Corp. made, YE9284400) treated with mitomycin C (Kyouwa Hakkou Corp. made) was seeded and cultured by using the culture medium for the feeder cell as described above at 37° C. in 5% CO 2 incubator (Tabai Espec Corp. made) for 5 hours or longer.
- the cynomolgus monkey ES cells (Tanabe Seiyaku, K.K. made) was seeded on mouse embryonic primary culture cell, and cultured and proliferated in 5 mL of cynomolgus monkey ES cell culture medium at 37° C. in 5% CO 2 incubator for 3 days.
- GFR Growth Factor Reduced
- BD Matrigel Becton Dickinson Japan made, 354230, Japan
- BD Matrigel basement membrane Matrix Becton Dickinson Japan made, 354234, Japan
- the Matrigel was diluted 20 folds by using cooled DMEM/F12 1:1 (Sigma Corp. made, D6421, USA), added to a culture dish, and incubated at room temperature for 1 hour. The solution was removed and the residue was washed with DMEM/F12 1:1 to obtain a Matrigel-coated dish.
- the cynomolgus monkey ES cells prepared by the method described in (2) preparation of cynomolgus monkey ES cells as described above were diluted 3 to 5 folds by adding the medium, and 4.5 mL (per dish) of the cell solution were seeded on a 6 cm-diameter cell culture dish coated previously with Matrigel (Becton Dickinson Japan made).
- the differentiation inhibiting agent (A to F and a to o) of the present invention and 6-bromoindirubin-3-oxime which were dissolved in dimethylsulfoxide (DMSO) or culture medium, or their mixture to make 8 to 40 ⁇ g/mL per each dish, was added, and culturing was carried out at 37° C. in 5% CO 2 incubator. Subculture was carried out for every 2 to 4 days by the method described in (2) preparation of cynomolgus monkey ES cells as described above. The final concentration of DMSO in the culture medium was 0.1% or lower.
- the cultured cells as described above were evaluated by the alkaline phosphatase staining described in Example 1 as described above.
- FIG. 15 The result of the alkaline phosphatase staining of the cells which were cultured for 2 days after the compound B or the compound f was added is presented in FIG. 15 as a proportion of number of stained colony to number of the total colony, and a photograph of the alkaline phosphatase staining at 3rd day after subculture after 3-day culture by adding the compound f in the absence or the presence of 6-bromoindirubin-3-oxime is shown in FIG. 16 .
- the cynomolgus monkey ES cells cultured with the differentiation inhibiting agent, the compound B and the compound f, of the present invention showed a significantly higher proportion of colonies stained with alkaline phosphatase, in comparison with the cynomolgus monkey ES cells cultured with DMSO (0.1%). Further, the cynomolgus monkey ES cells subcultured in the presence of the compound f was stained significantly in comparison with the cynomolgus monkey ES cells subcultured in the presence of DMSO. Moreover, in the presence of 6-bromoindirubin-3-oxime, the effect of the compound f was reinforced.
- the differentiation inhibiting agent of the present invention supported the undifferentiated state of the cynomolgus monkey ES cells.
- the same examination was carried out for the compounds A, C to E, a to e and g to o, and the alkaline phosphatase activity was maintained similarly to the differentiation inhibiting agents B and f. It was shown that these differentiation inhibiting agents maintained the undifferentiation state of the cynomolgus monkey ES cell.
- 2-cyanoacetamide (Aldrich Corp. made, USA) is added to benzene, and concentrated sulfuric acid is slowly dropped to prevent a rise of the temperature to 10° C. with stirring.
- the solution is cooled to room temperature, and then dimethylbenzylcarbinol (Lancaster Corp. made, UK) is added. After refluxed for about 30 minutes, the solution is left stand for cooling to room temperature and, then, the reaction mixture is poured into ice water. A water phase extracted is neutralized and the resultant precipitation is filtered. After drying, the precipitation is recrystallized by using isopropanol to obtain the title compound.
- p-aminoacetophenon (Aldrich Corp., USA) is added to benzene, and hydrochloric acid gas is passed. The obtained precipitation is filtered and recrystallized with isopropanol to obtain p-aminoacetophenon hydrochloride.
- the obtained p-aminoacetophenon hydrochloride is dissolved in a 20% aqueous ethanol solution, and made it acidic by adding concentrated hydrochloric acid on an ice bath. An aqueous sodium nitrite solution is dropped and urea treatment is carried out to obtain a diazonium salt solution.
- 3,3-dimethyl-1,2,3,4-tetrahydroisoquinolinidene-1-acetamide is dissolved in a 20% aqueous ethanol solution, and concentrated hydrochloric acid is added.
- the temperature is regulated to prevent to exceed 10° C. and the above diazonium salt solution is added.
- the reaction solution changes, and a saturated aqueous sodium acetate solution is added with stirring.
- the obtained precipitation is filtered and, then, recrystallized by isopropanol to obtain the title compound.
- m-aminoacetophenon (Aldrich Corp., USA) is added to benzene and hydrochloric acid gas is passed. The obtained precipitation is filtered and recrystallized with isopropanol to obtain p-aminoacetophenon hydrochloride.
- the obtained p-aminoacetophenon hydrochloride is dissolved in a 20% aqueous ethanol solution and made it acidic by adding concentrated hydrochloric acid on an ice bath. An aqueous sodium nitrite solution is dropped, and urea treatment is carried out to obtain a diazonium salt solution.
- 3,3-dimethyl-1,2,3,4-tetrahydroisoquinolinidene-1-acetamide is dissolved in a 20% aqueous ethanol solution, and concentrated hydrochloric acid is added.
- the temperature is regulated to prevent to exceed 10° C., and the above diazonium salt solution is added.
- the reaction solution changes, and a saturated aqueous sodium acetate solution is added by stirring.
- the obtained precipitation is filtered and, then, recrystallized by isopropanol to obtain the title compound.
- the 5 mL-ES cell culture medium was added, the cell colonies were dispersed by using a pipette with a small diameter and transferred to a 15 mL-sterilized tube, and centrifuged at 800 rpm for about 5 minutes by using the table centrifuge (TOMY SEIKO K.K.) to make pellets.
- the supernatant was discarded, cells were suspended again in a 5 mL fresh ES cell culture medium and seeded on a 10 cm-diameter dish for cell culture, which had been previously coated with a 0.1% gelatin aqueous solution, and incubated at 37° C. for 20 minutes. After 20 minutes, the culture medium containing floating cells was collected by using a pipette, transferred to a 15 mL-sterilized tube, centrifuged at 1000 rpm for about 5 minutes by using the table centrifuge to make the pellets. Then, the supernatant was removed followed by suspending again in a 5 mL-ES cell assay medium.
- 3 ⁇ 10 2 to 1 ⁇ 10 3 cells/well were seeded on a 24-well cell culture dish (Falcon Corp. made, Cat. No. 3047, USA), which had been coated previously with a 0.1% aqueous gelatin solution, to make the ES cell assay medium in 500 ⁇ L/1 well.
- 50 ⁇ L of the compounds ⁇ circle over (1) ⁇ to ⁇ circle over (10) ⁇ which were prepared by the method described in Example 6, dissolved in dimethylsulfoxide (DMSO) or water, or their mixture to make 0.4 to 40 ⁇ g/mL per each well, or ESGRO was added, and culturing was carried out at 37° C. in 5% CO 2 incubator for 7 days.
- the final concentration of DMSO in the culture medium was 0.1% or lower.
- the ES cells were stained by using an alkaline phosphatase kit (SIGMA Diagnostic Corp. made, Cat. No. 86-R).
- the medium was removed by sucking from individual wells of the ES cells cultured by the method described in the “ES cell differentiation inhibitor assay” as described above, and the cells were washed once with 0.5 mL of phosphate buffered saline (PBS) and, then, 0.5 mL of a cell-fixing solution (25 mL citric acid solution (SIGMA Corp. made, Cat. No. 91-5), 65 mL acetone and 8 mL 37% formaldehyde) was added to each well, and the cells were left stand at room temperature for 30 seconds.
- PBS phosphate buffered saline
- a cell-fixing solution 25 mL citric acid solution (SIGMA Corp. made, Cat. No. 91-5), 65 mL acetone and 8 mL 37% formaldehyde
- the fixing solution was removed by sucking, and 0.5 mL of deionized water was added to individual wells and left stand at room temperature for 45 seconds.
- the deionized water was removed by sucking and, then, 0.5 mL of an alkaline phosphatase staining solution (1 mL sodium nitrite solution, 1 mL Fast Red Violet LB salt solution, 1 mL naphthol AS-BI alkaline solution and 45 mL distilled water) was added to each well and left stand at room temperature for 15 minutes followed by removal of the staining solution by sucking, and washing was carried out with 0.5 mL of deionized water.
- an alkaline phosphatase staining solution (1 mL sodium nitrite solution, 1 mL Fast Red Violet LB salt solution, 1 mL naphthol AS-BI alkaline solution and 45 mL distilled water
- Staining images were compared among the ES cells as the negative control cultured in the absence of ESGRO, the ES cells as the positive control cultured in the presence of ESGRO (1000 units/mL), and the ES cells cultured in the presence of the compound ⁇ circle over (4) ⁇ (4 ⁇ g/mL) of the present invention (refer to FIG. 19 ).
- the ES cells cultured in the presence of the compound ⁇ circle over (4) ⁇ was, in comparison with the ES cells cultured in the absence of ESGRO, were stained significantly more densely, showing that the ES cells have a high alkaline phosphatase activity.
- the compound of the present invention also allowed the cells to form the undifferentiated colony equal to that of the ES cells cultured in the presence of ESGRO being the positive control. From this result, the compound of the present invention supported strongly proliferation of the ES cells in the undifferentiated state.
- the stem cell preferably the embryonic stem cell
- the differentiation inhibiting agent, the culture method by using the same, and the culture liquid, which are provided by the present invention can be applied to produce the stem cell, preferably the embryonic stem cell, as a cell source of uses for cell transplantation.
- the differentiation inhibiting agent and the culture method by using the same can be applied to produce the embryonic stem cell having 1 or more genetic modifications.
- the application includes, for example, developing a cell-based model related to a disease and developing a tissue specified to transplantation for treating a genetic disease, however, is not restricted to them.
- the differentiation inhibiting agent and/or the bicyclic compounds of the present invention can proliferate the stem cell in the undifferentiated state and, as the result, cells and tissues cultured can be preferably used for regeneration medical field.
- the compound can be applied to a pharmaceutical composition.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/233,252 US8883504B2 (en) | 2003-06-27 | 2008-09-18 | Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-185398 | 2003-06-27 | ||
JP2003185398 | 2003-06-27 | ||
JP2003353870 | 2003-10-14 | ||
JP2003-353870 | 2003-10-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/233,252 Division US8883504B2 (en) | 2003-06-27 | 2008-09-18 | Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050153941A1 true US20050153941A1 (en) | 2005-07-14 |
Family
ID=34082299
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/875,194 Abandoned US20050153941A1 (en) | 2003-06-27 | 2004-06-25 | Cell differntiation inhibiting agent, cell culture method using the same, culture medium, and cultured cell line |
US12/233,252 Active 2029-04-14 US8883504B2 (en) | 2003-06-27 | 2008-09-18 | Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/233,252 Active 2029-04-14 US8883504B2 (en) | 2003-06-27 | 2008-09-18 | Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line |
Country Status (6)
Country | Link |
---|---|
US (2) | US20050153941A1 (ja) |
EP (1) | EP1640449A4 (ja) |
JP (1) | JP4667241B2 (ja) |
KR (1) | KR101160698B1 (ja) |
AU (1) | AU2004257966B2 (ja) |
WO (1) | WO2005007838A1 (ja) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007062243A2 (en) * | 2005-11-28 | 2007-05-31 | Choongwae Pharma Corporation | Serum-free expansion of cells in culture |
US20090318455A1 (en) * | 2008-06-03 | 2009-12-24 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US20100087502A1 (en) * | 2007-03-07 | 2010-04-08 | Glaxo Group Limited | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders |
US20110172611A1 (en) * | 2010-01-08 | 2011-07-14 | Yoo James J | Delivery system |
WO2012122105A1 (en) | 2011-03-07 | 2012-09-13 | Wake Forest University Health Sciences | Delivery system |
US8741936B2 (en) | 2005-05-10 | 2014-06-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US20160053230A1 (en) * | 2014-06-27 | 2016-02-25 | National University Corporation Chiba University | Culture Medium And Method For Inducing Differentiation of Pluripotent Stem Cells To Hepatoblasts |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
WO2022072491A1 (en) * | 2020-09-30 | 2022-04-07 | Metacrine, Inc. | Hsd17b13 inhibitors and uses thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006204292A (ja) * | 2004-12-27 | 2006-08-10 | Asahi Kasei Corp | ヒト胚性幹細胞分化抑制剤 |
JP5107589B2 (ja) * | 2007-02-13 | 2012-12-26 | 旭化成株式会社 | インドール誘導体 |
US9435493B2 (en) | 2009-10-27 | 2016-09-06 | Cree, Inc. | Hybrid reflector system for lighting device |
WO2015194710A1 (ko) * | 2014-06-17 | 2015-12-23 | 가톨릭대학교 산학협력단 | Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
KR101705412B1 (ko) * | 2014-06-17 | 2017-02-09 | 가톨릭대학교 산학협력단 | Stat3 억제제가 처리된 간엽줄기세포를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 |
MX2021011775A (es) | 2017-04-26 | 2023-01-10 | Basilea Pharm Int Ag | Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos. |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030082810A1 (en) * | 2001-02-26 | 2003-05-01 | Palle Serup | Methods for generating insulin-secreting cells suitable for transplantation |
US20040028660A1 (en) * | 2002-05-30 | 2004-02-12 | Anthrogenesis Corporation | Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
US20040097408A1 (en) * | 2001-01-03 | 2004-05-20 | Philip Leder | Compounds regulating cell proliferation and differentiation |
US20060195918A1 (en) * | 2005-01-18 | 2006-08-31 | Princeton University | Embryonic stem cell self maintenance and renewal reporter |
US20070178439A1 (en) * | 2003-10-16 | 2007-08-02 | Smith Austin G | Control of es cell self renewal and lineage specification, and medium therefor |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4866048A (en) * | 1985-08-02 | 1989-09-12 | Leo Pharmaceutical Products Ltd. | Novel vitamin D analogues |
US4667083A (en) * | 1986-02-14 | 1987-05-19 | Westinghouse Electric Corp. | Torch for preheating a continuously fed welding wire |
AU1197699A (en) | 1997-10-23 | 1999-05-10 | Geron Corporation | Methods and materials for the growth of primate-derived primordial stem cells |
US6667176B1 (en) * | 2000-01-11 | 2003-12-23 | Geron Corporation | cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells |
AU2002317039B2 (en) * | 2001-07-24 | 2007-10-04 | Es Cell International Pte Ltd | Methods of inducing differentiation of stem cells |
MXPA04000982A (es) * | 2001-07-31 | 2004-04-20 | Anormed Inc | Metodos para movilizar celulas progenitoras/madre. |
WO2003038070A1 (fr) | 2001-10-31 | 2003-05-08 | Asahi Kasei Kabushiki Kaisha | Materiau de base pour culture de cellules souches embryonnaires et procede de culture |
AUPS209402A0 (en) | 2002-05-02 | 2002-06-06 | Victor Chang Cardiac Research Institute, The | Cell differentiation and self renewal |
CA2488425A1 (en) | 2002-06-07 | 2003-12-18 | Es Cell International Pte Ltd | Methods of regulating differentiation in stem cells |
WO2005085422A1 (en) * | 2004-02-27 | 2005-09-15 | Michigan State University | Adult stem cells and uses thereof |
SE0950586L (sv) * | 2007-01-17 | 2009-08-13 | Wisconsin Alumni Res Found | Förbättrad odling av stamceller |
-
2004
- 2004-06-25 WO PCT/JP2004/009379 patent/WO2005007838A1/ja active Application Filing
- 2004-06-25 JP JP2005511810A patent/JP4667241B2/ja not_active Expired - Lifetime
- 2004-06-25 AU AU2004257966A patent/AU2004257966B2/en not_active Expired
- 2004-06-25 EP EP04746848A patent/EP1640449A4/en not_active Withdrawn
- 2004-06-25 US US10/875,194 patent/US20050153941A1/en not_active Abandoned
- 2004-06-25 KR KR1020057024980A patent/KR101160698B1/ko active IP Right Grant
-
2008
- 2008-09-18 US US12/233,252 patent/US8883504B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040097408A1 (en) * | 2001-01-03 | 2004-05-20 | Philip Leder | Compounds regulating cell proliferation and differentiation |
US20030082810A1 (en) * | 2001-02-26 | 2003-05-01 | Palle Serup | Methods for generating insulin-secreting cells suitable for transplantation |
US20040028660A1 (en) * | 2002-05-30 | 2004-02-12 | Anthrogenesis Corporation | Methods of using JNK or MKK inhibitors to modulate cell differentiation and to treat myeloproliferative disorders and myelodysplastic syndromes |
US20070178439A1 (en) * | 2003-10-16 | 2007-08-02 | Smith Austin G | Control of es cell self renewal and lineage specification, and medium therefor |
US20060195918A1 (en) * | 2005-01-18 | 2006-08-31 | Princeton University | Embryonic stem cell self maintenance and renewal reporter |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9527816B2 (en) | 2005-05-10 | 2016-12-27 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US10010536B2 (en) | 2005-05-10 | 2018-07-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US8741936B2 (en) | 2005-05-10 | 2014-06-03 | Intermune, Inc. | Method of modulating stress-activated protein kinase system |
US20070128669A1 (en) * | 2005-11-28 | 2007-06-07 | Institute For Chemical Genomics | Serum-free expansion of cells in culture |
WO2007062243A3 (en) * | 2005-11-28 | 2007-08-09 | Inst Chemical Genomics | Serum-free expansion of cells in culture |
JP2009517085A (ja) * | 2005-11-28 | 2009-04-30 | チョンウェ ファーマ コーポレイション | 培養における細胞の無血清増殖 |
WO2007062243A2 (en) * | 2005-11-28 | 2007-05-31 | Choongwae Pharma Corporation | Serum-free expansion of cells in culture |
US20100087502A1 (en) * | 2007-03-07 | 2010-04-08 | Glaxo Group Limited | Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders |
US7960563B2 (en) | 2007-03-07 | 2011-06-14 | Glaxo Group Limited | Indazoles used to treat estrogen receptor beta mediated disorders |
US9290450B2 (en) | 2008-06-03 | 2016-03-22 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8969347B2 (en) | 2008-06-03 | 2015-03-03 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
USRE47142E1 (en) | 2008-06-03 | 2018-11-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US8304413B2 (en) | 2008-06-03 | 2012-11-06 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US20090318455A1 (en) * | 2008-06-03 | 2009-12-24 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
US20110172611A1 (en) * | 2010-01-08 | 2011-07-14 | Yoo James J | Delivery system |
US10500384B2 (en) | 2010-01-08 | 2019-12-10 | Wake Forest University Health Sciences | Delivery system |
US11759579B2 (en) | 2011-03-07 | 2023-09-19 | Wake Forest University Health Sciences | Delivery system |
US10118005B2 (en) | 2011-03-07 | 2018-11-06 | Wake Forest University Health Sciences | Delivery system |
US10537689B2 (en) | 2011-03-07 | 2020-01-21 | Wake Forest University Health Sciences | Delivery system |
WO2012122105A1 (en) | 2011-03-07 | 2012-09-13 | Wake Forest University Health Sciences | Delivery system |
US9359379B2 (en) | 2012-10-02 | 2016-06-07 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10376497B2 (en) | 2012-10-02 | 2019-08-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US9675593B2 (en) | 2012-10-02 | 2017-06-13 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10898474B2 (en) | 2012-10-02 | 2021-01-26 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10233195B2 (en) | 2014-04-02 | 2019-03-19 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10544161B2 (en) | 2014-04-02 | 2020-01-28 | Intermune, Inc. | Anti-fibrotic pyridinones |
US10006005B2 (en) * | 2014-06-27 | 2018-06-26 | National University Corporation Chiba University | Culture medium and method for inducing differentiation of pluripotent stem cells to hepatoblasts |
US20160053230A1 (en) * | 2014-06-27 | 2016-02-25 | National University Corporation Chiba University | Culture Medium And Method For Inducing Differentiation of Pluripotent Stem Cells To Hepatoblasts |
WO2022072491A1 (en) * | 2020-09-30 | 2022-04-07 | Metacrine, Inc. | Hsd17b13 inhibitors and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
JP4667241B2 (ja) | 2011-04-06 |
AU2004257966A1 (en) | 2005-01-27 |
EP1640449A4 (en) | 2009-03-25 |
KR20060056901A (ko) | 2006-05-25 |
KR101160698B1 (ko) | 2012-06-28 |
JPWO2005007838A1 (ja) | 2006-08-31 |
US20090155906A1 (en) | 2009-06-18 |
US8883504B2 (en) | 2014-11-11 |
WO2005007838A1 (ja) | 2005-01-27 |
AU2004257966B2 (en) | 2008-10-02 |
EP1640449A1 (en) | 2006-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8883504B2 (en) | Cell differentiation suppressing agent, method of culturing cells using the same, culture solution, and cultured cell line | |
US10947506B2 (en) | Human cardiovascular progenitor cells | |
JP2021104021A (ja) | 軟骨細胞系統細胞及び/又は軟骨様組織を作製するための方法及び組成物 | |
JP7549442B2 (ja) | ヒト腸神経堤系統由来多能性幹細胞によって可能にされるヒルシュスプルング病における細胞ベースの処置および薬物発見 | |
WO2019017492A1 (ja) | 連続的な上皮を含む網膜組織の成熟化方法 | |
US20160194608A1 (en) | Methods for Inducing Cardiomyogenesis | |
JP5107589B2 (ja) | インドール誘導体 | |
JP2006204292A (ja) | ヒト胚性幹細胞分化抑制剤 | |
KR100980005B1 (ko) | 배아줄기세포를 심근세포로 분화 유도하는 방법 | |
US20230136878A1 (en) | Cardiomyocyte purification method | |
WO2012157612A1 (ja) | 細胞分化誘導剤および分化誘導方法 | |
CN117157388A (zh) | 卵巢体细胞样细胞的制造方法及将灵长类多能干细胞分化诱导成卵巢体细胞样细胞的方法 | |
JP2005013152A (ja) | 細胞分化抑制剤及びこれを用いた細胞培養方法、培養液、培養された細胞 | |
JP7365367B2 (ja) | 褐色脂肪細胞の産生 | |
JP4406601B2 (ja) | 組織幹細胞増殖剤 | |
RU2813532C1 (ru) | Способ очистки кардиомиоцитов | |
WO2021187602A1 (ja) | 心筋細胞の精製方法 | |
JP2005000034A (ja) | 全能性幹細胞培養用フィーダー |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ASAHI KASEI KABUSHIKI KAISHA, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MIYABAYASHI, TOMOYUKI;YAMAMOTO, MASASHI;REEL/FRAME:016277/0110 Effective date: 20050201 |
|
AS | Assignment |
Owner name: ASAHI KASEI KABUSHIKI KAISHA, JAPAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MIYABASHI, TOMOYUKI;YAMAMOTO, MASASHI;REEL/FRAME:016584/0106 Effective date: 20050201 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |